instruction stringlengths 152 1.77k | input stringlengths 222 3.27k | response stringclasses 11 values |
|---|---|---|
<Instruct>: Given the context 'Ligand binding leads to phosphorylation and activation of type I receptors, which, in turn, phosphorylate and activate a specific set of downstream signaling molecules called Smads.', select the correct biomedical concept corresponding to 'signaling molecules'. Answer using one of the provided options. | <Options>: A: cis-ddp (aka cisplatin)
B: alpha-antiarin (c[c@h]1o[c@@h](o[c@h]2cc[c@]3(c=o)[c@h]4c[c@@h](o)[c@]5(c)[c@h](cc[c@]5(o)[c@@h]4cc[c@]3(o)c2)c2=cc(=o)oc2)[c@h](o)[c@h](o)[c@h]1o) (aka alpha-antiarin)
C: phospholipase a inhibitor (aka ec 3.1.1.4 (phospholipase a2) inhibitor)
D: biomineral (aka biogenic mineral)
E: waxes (aka wax)
F: nickel dichloride (nickel(2+) chloride) (aka nickel dichloride)
G: 1-alkyl-glycerones (aka o-alkylglycerone)
H: c30h44o7 (aka adynerin)
I: c6h24n6ni (aka tris(ethane-1,2-diamine)nickel(2+))
J: trans-platinum(ii) ammonium chloride (aka transplatin)
K: None of the above. | K |
<Instruct>: Given the context 'To determine, if ALK5-mediated TGF-β-signaling had a role in development of the OFT and large vessels of the aortic arch, we performed casting dye experiments on E17 embryos (Fig.', select the correct biomedical concept corresponding to 'dye'. Answer using one of the provided options. | <Options>: A: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
B: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
C: ergot alkaloid (ergot alkaloids) (aka ergot alkaloid)
D: ec 3.1.4.53 inhibitor (aka ec 3.1.4.53 (3',5'-cyclic-amp phosphodiesterase) inhibitor)
E: inhibitor of phosphoric monoester hydrolase (ec 3.1.3.*) (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
F: milli-calpain inhibitors (aka ec 3.4.22.53 (calpain-2) inhibitor)
G: smase inhibitors (aka ec 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor)
H: hemiterpenoid indole alkaloids (aka hemiterpenoid indole alkaloid)
I: fructose 1,6-bisphosphatase inhibitor (aka ec 3.1.3.11 (fructose-bisphosphatase) inhibitor)
J: None of the above. | J |
<Instruct>: Given the context 'A-D, Casting-dye analysis of OFT morphogenesis at E17.0.', select the correct biomedical concept corresponding to 'dye'. Answer using one of the provided options. | <Options>: A: ec 3.1.4.53 inhibitor (aka ec 3.1.4.53 (3',5'-cyclic-amp phosphodiesterase) inhibitor)
B: milli-calpain inhibitors (aka ec 3.4.22.53 (calpain-2) inhibitor)
C: hemiterpenoid indole alkaloids (aka hemiterpenoid indole alkaloid)
D: inhibitor of phosphoric monoester hydrolase (ec 3.1.3.*) (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
E: fructose-bisphosphatase inhibitors (aka ec 3.1.3.11 (fructose-bisphosphatase) inhibitor)
F: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
G: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
H: ergot alkaloid (ergot alkaloids) (aka ergot alkaloid)
I: smase inhibitors (aka ec 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor)
J: None of the above. | J |
<Instruct>: Given the context 'A-B, frontal image of ink-injected embryos; C-D, frontal sections (H&E staining).', select the correct biomedical concept corresponding to 'h'. Answer using one of the provided options. | <Options>: A: c11h13n (aka pargyline)
B: guanyl-specific rnase inhibitors (aka ec 3.1.27.3 (ribonuclease t1) inhibitor)
C: diphenhydramine theoclate (aka dimenhydrinate)
D: phenoxybenzamine (cc(coc1ccccc1)n(cccl)cc1ccccc1) (aka phenoxybenzamine)
E: c6h12o6 (aka fuconic acid)
F: oxydemeton methyl (aka oxydemeton-methyl)
G: (-)-carbovir triphosphate (aka carbovir triphosphate)
H: [h][c@]12nc3nc(n)[nh]c(=o)c3n[c@@]1([h])c(s)=c(s)[c@@h](cop(o)(o)=o)o2 (aka molybdopterin)
I: organic sulfate salt (organic sulfate salts) (aka organic sulfate salt)
J: 3-amino-1,2,4-benzotriazine 1,4-dioxide (aka tirapazamine)
K: None of the above. | K |
<Instruct>: Given the context 'A, C, E, G, I, K, M, O, Q, H&E staining; B, D, F, H, J, L, N, P, R, double staining for αSMA (brown) and β-galactosidase (green; R26R reporter assay).', select the correct biomedical concept corresponding to 'h'. Answer using one of the provided options. | <Options>: A: phenoxybenzamine (cc(coc1ccccc1)n(cccl)cc1ccccc1) (aka phenoxybenzamine)
B: diphenhydramine theoclate (aka dimenhydrinate)
C: 3-amino-1,2,4-benzotriazine 1,4-dioxide (aka tirapazamine)
D: c6h12o6 (aka fuconic acid)
E: oxydemeton methyl (aka oxydemeton-methyl)
F: organic sulfate salt (organic sulfate salts) (aka organic sulfate salt)
G: guanyl-specific rnase inhibitors (aka ec 3.1.27.3 (ribonuclease t1) inhibitor)
H: cn(cc#c)cc1ccccc1 (aka pargyline)
I: carbovir 5'-triphosphate (aka carbovir triphosphate)
J: [h][c@]12nc3nc(n)[nh]c(=o)c3n[c@@]1([h])c(s)=c(s)[c@@h](cop(o)(o)=o)o2 (aka molybdopterin)
K: None of the above. | K |
<Instruct>: Given the context 'To analyze whether this phenotype resulted either from defective CNCC proliferation or inappropriate apoptosis, we used BrdU and TUNEL staining, respectively.', select the correct biomedical concept corresponding to 'brdu'. Answer using one of the provided options. | <Options>: A: oc[c@@h](o)[c@@h](o[c@h]1o[c@h](co)[c@@h](o[c@h]2o[c@h](co)[c@@h](o[c@h]3o[c@h](co)[c@@h](o[c@h]4o[c@h](co)[c@@h](o)[c@h](o)[c@h]4o)[c@h](o)[c@h]3o)[c@h](o)[c@h]2o)[c@h](o)[c@h]1o)[c@h](o)[c@@h](o)c=o (aka maltopentaose)
B: ec 2.1.1.72 [site-specific dna-methyltransferase (adenine-specific)] inhibitors (aka ec 2.1.1.72 [site-specific dna-methyltransferase (adenine-specific)] inhibitor)
C: mannooligosaccharide (mannosyloligosaccharides) (aka mannooligosaccharide)
D: cccccoc(=o)coc1cc(n2c(=o)c3=c(cccc3)c2=o)c(f)cc1cl (aka flumiclorac pentyl)
E: alpha-l-rhap-(1->2)-alpha-l-rhap (c[c@@h]1o[c@@h](o)[c@h](o[c@@h]2o[c@@h](c)[c@h](o)[c@@h](o)[c@h]2o)[c@h](o)[c@h]1o) (aka alpha-l-rhap-(1->2)-alpha-l-rhap)
F: beta-d-galactosyl-(1->4)-l-rhamnose (c[c@@h]1oc(o)[c@h](o)[c@h](o)[c@h]1o[c@@h]1o[c@h](co)[c@h](o)[c@h](o)[c@h]1o) (aka beta-d-galactosyl-(1->4)-l-rhamnose)
G: (2s,2's)-2,2'-bioxirane (aka (s,s)-diepoxybutane)
H: glycosyl rhamnose (aka glycosylrhamnose)
I: None of the above. | I |
<Instruct>: Given the context 'A and D, hematoxyllin and eosin staining; B and E, R26 R lineage tracing assay – counterstaining with eosin; C and F, section in situ hybridization for PTH – counterstaining with eosin.', select the correct biomedical concept corresponding to 'hematoxyllin'. Answer using one of the provided options. | <Options>: A: n-[(2s,3r,4e)-1-{[2-acetamido-2-deoxy-3-o-sulfo-alpha-d-galactopyranosyl-(1->4)-3-o-sulfo-beta-d-galactopyranosyl-(1->4)-beta-d-glucopyranosyl]oxy}-3-hydroxyoctadec-4-en-2-yl]alkanamide (aka ganglioside ga2 ii3,iii3-bis-sulfate)
B: nucleoside q (q (aka nucleoside q))
C: dihydroergocristine mesylate (cs(o)(=o)=o.[h][c@@]12cc3c[nh]c4cccc(c34)[c@@]1([h])c[c@h](cn2c)c(=o)n[c@@]1(o[c@]2(o)n([c@@h](cc3ccccc3)c(=o)n3ccc[c@@]23[h])c1=o)c(c)c) (aka dihydroergocristine mesylate)
D: homocysteinate (2-amino-4-sulfanylbutanoate) (aka homocysteinate)
E: [h][p+][h] (aka phosphanylium)
F: cc(o)c(c)=o (aka acetoin)
G: n-[(2s,3r,4e)-1-{[2-acetamido-2-deoxy-3-o-sulfo-alpha-d-galactopyranosyl-(1->4)-beta-d-galactopyranosyl-(1->4)-beta-d-glucopyranosyl]oxy}-3-hydroxyoctadec-4-en-2-yl]alkanamide (aka ganglioside ga2 iii3-sulfate)
H: 7-deazaguanine ribonucleosides (aka 7-deazaguanine ribonucleoside)
I: queuosine (aka queuosine residue)
J: o-5''-beta-d-mannosylqueuosine ((1r,2s,5s)-2-({[2-amino-4-oxo-7-(beta-d-ribofuranosyl)-4,7-dihydro-3h-pyrrolo[2,3-d]pyrimidin-5-yl]methyl}amino)-5-hydroxycyclopent-3-en-1-yl beta-d-mannopyranoside) (aka o-5''-beta-d-mannosylqueuosine)
K: None of the above. | K |
<Instruct>: Given the context 'Females were euthanized by CO2, and embryos were collected in Hanks' balanced salt solution on ice.
', select the correct biomedical concept corresponding to 'co2'. Answer using one of the provided options. | <Options>: A: methyl 13-sophorosyloxydocosanoate (cccccccccc(cccccccccccc(=o)oc)o[c@@h]1o[c@h](co)[c@@h](o)[c@h](o)[c@h]1o[c@@h]1o[c@h](co)[c@@h](o)[c@h](o)[c@h]1o) (aka methyl 13-sophorosyloxydocosanoate)
B: n-(decanoyl)sphing-4-enine (aka n-decanoylsphingosine)
C: c38h68o15 (aka 13-sophorosyloxydocosanoate 6',6''-diacetate)
D: iodobenzoate (iodobenzoates) (aka iodobenzoate)
E: c14h8o7s (aka alizarin red)
F: c34h64o13 (aka 13-sophorosyloxydocosanoic acid)
G: cl6h8irn2 (aka ammonium hexachloroiridate)
H: sophorolipids (aka sophorolipid)
I: cc(c)cccccccccc[c@@h](o)[c@@h](o)[c@h](co[c@@h]1o[c@h](co)[c@@h](o)[c@h](o)[c@h]1o)nc([*])=o (aka n-hexacosadienoyl-1-o-beta-d-glucosyl-4-hydroxy-15-methylhexadecasphinganine)
J: None of the above. | J |
<Instruct>: Given the context 'Histological analyses
Embryos (E17) were fixed with 4% paraformaldehyhe for 14 hours, dehydrated and embedded in paraffin wax.', select the correct biomedical concept corresponding to 'wax'. Answer using one of the provided options. | <Options>: A: n(6),n(6)-dimethyladenosine 5'-monophosphate(1-) residue (n(6)-dimethyladenosine 5'-phosphate residue) (aka n(6),n(6)-dimethyladenosine 5'-monophosphate(1-) residue)
B: aryl bromides (aka bromoarene)
C: 1,5-lactones (aka delta-lactone)
D: (2s,5',s)-2-amino-3-(3-carboxy-2-isoxazolin-5-yl)propanoic acid (aka (5s)-5-[(2s)-2-amino-2-carboxyethyl]-4,5-dihydroisoxazole-3-carboxylic acid)
E: 9alpha-hydroxy-3-oxo-23,24-bisnorchola-1,4-dien-22-oic acid (c[c@@h]([c@h]1cc[c@h]2[c@@h]3ccc4=cc(=o)c=c[c@]4(c)[c@@]3(o)cc[c@]12c)c(o)=o) (aka 9alpha-hydroxy-3-oxo-23,24-bisnorchola-1,4-dien-22-oic acid)
F: 4-chlorodiphenyl (aka 4-chlorobiphenyl)
G: 2-hydroxycetyl palmitate (aka 2-hydroxypalmityl palmitate)
H: c22h32o4 (aka 9alpha-hydroxy-3-oxo-23,24-bisnorchol-4-en-22-oic acid)
I: androst-4-ene-3,17-dione-11beta-ol (aka 11beta-hydroxyandrost-4-ene-3,17-dione)
J: c12h16o5 (aka 2-(2-carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic acid)
K: None of the above. | K |
<Instruct>: Given the context 'Sections (7–8 um) were stained with Hematoxylin and Eosin (n≥3 for each genotype).', select the correct biomedical concept corresponding to 'hematoxylin'. Answer using one of the provided options. | <Options>: A: 2,3-dihydro-2,2-dimethyl-7-hydroxybenzofuran (aka 2,2-dimethyl-2,3-dihydro-1-benzofuran-7-ol)
B: nc1nc2n(cc(cn[c@h]3c=c[c@h](o)[c@@h]3o)c2c(=o)[nh]1)[c@@h]1o[c@h](co)[c@@h](o)[c@h]1o (aka queuosine)
C: dynacin (aka minocycline hydrochloride)
D: acid sphingomyelinase inhibitors (aka ec 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor)
E: hexobarbital (5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1h,3h,5h)-trione) (aka hexobarbital)
F: coc1cccc2cc(oc(=o)c12)c1ccc(o)cc1 (aka scorzotomentosin, (rac)-)
G: sodium (n,n,n',n'-ethylenediaminetetraacetato)ferrate(1-) (aka sodium feredetate)
H: 7-acetyl-5-[(1s)-1-hydroxyethyl]-3,4-dihydroisochromen-1-one (aka swerilactone m)
I: swerilactone n (5-[(1s)-1-hydroxy-3-oxobutyl]-3,4-dihydroisochromen-1-one) (aka swerilactone n)
J: cc1(c)cc2ccccc2o1 (aka 2,2-dimethyl-2,3-dihydrobenzofuran)
K: None of the above. | K |
<Instruct>: Given the context 'Briefly, the specimens (E11.0 – E11.5) were fixed in 4% paraformaldehyde for 30 minutes at room temperature, washed 3 times for 10 minutes in the detergent wash and developed for 2–12 hours in X-gal solution (n≥3 for each genotype).', select the correct biomedical concept corresponding to 'detergent'. Answer using one of the provided options. | <Options>: A: ec 2.1.1.122 ((s)-tetrahydroprotoberberine n-methyltransferase) inhibitor (aka ec 2.1.1.122 [(s)-tetrahydroprotoberberine n-methyltransferase] inhibitor)
B: trans-ddp (aka transplatin)
C: milli-calpain inhibitors (aka ec 3.4.22.53 (calpain-2) inhibitor)
D: phosphatase iii inhibitor (aka ec 3.1.3.16 (phosphoprotein phosphatase) inhibitor)
E: endoamylase inhibitor (aka ec 3.2.1.1 (alpha-amylase) inhibitor)
F: mttp inhibitors (aka mtp inhibitor)
G: curium (aka curium atom)
H: primary metabolites (aka metabolite)
I: wiskott-aldrich syndrome protein inhibitor (wiskott-aldrich syndrome protein inhibitors) (aka wiskott-aldrich syndrome protein inhibitor)
J: alpha-carboxylesterase inhibitor (aka ec 3.1.1.1 (carboxylesterase) inhibitor)
K: None of the above. | K |
<Instruct>: Given the context 'Briefly, the specimens (E11.0 – E11.5) were fixed in 4% paraformaldehyde for 30 minutes at room temperature, washed 3 times for 10 minutes in the detergent wash and developed for 2–12 hours in X-gal solution (n≥3 for each genotype).', select the correct biomedical concept corresponding to 'x-gal'. Answer using one of the provided options. | <Options>: A: environmental contaminants (aka environmental contaminant)
B: antimuon (positive muon) (aka antimuon)
C: lepton (leptons) (aka lepton)
D: cyclyl groups (aka cyclyl group)
E: beta(-) (aka electron)
F: 2'-deoxy-2',2'-difluorouridine (aka 2',2'-difluoro-2'-deoxyuridine)
G: maltooligosaccharides (aka maltooligosaccharide)
H: beta-d-glcp-(1->4)-[l-alpha-d-hepp-(1->3)]-l-alpha-d-hepp (oc[c@h](o)[c@h]1o[c@h](o[c@@h]2[c@h](o)[c@@h](o)o[c@h]([c@@h](o)co)[c@h]2o[c@@h]2o[c@h](co)[c@@h](o)[c@h](o)[c@h]2o)[c@@h](o)[c@@h](o)[c@@h]1o) (aka beta-d-glcp-(1->4)-[l-alpha-d-hepp-(1->3)]-l-alpha-d-hepp)
I: persistent organic pollutant (pops (aka persistent organic pollutant))
J: explosive material (aka explosive)
K: None of the above. | K |
<Instruct>: Given the context 'Briefly, the specimens (E11.0 – E11.5) were fixed in 4% paraformaldehyde for 30 minutes at room temperature, washed 3 times for 10 minutes in the detergent wash and developed for 2–12 hours in X-gal solution (n≥3 for each genotype).', select the correct biomedical concept corresponding to 'solution'. Answer using one of the provided options. | <Options>: A: ec 3.5.1.98 inhibitors (aka ec 3.5.1.98 (histone deacetylase) inhibitor)
B: protein synthesis inhibitor (protein synthesis antagonists) (aka protein synthesis inhibitor)
C: nadh cytochrome c oxidase inhibitors (aka ec 1.9.3.1 (cytochrome c oxidase) inhibitor)
D: phosphomonoesterase inhibitor (aka ec 3.1.3.1 (alkaline phosphatase) inhibitor)
E: tetrakis(trifluoridophosphorus)nickel (aka tetrakis(trifluorophosphane)nickel)
F: silikate (aka silicate mineral)
G: glycosylase (ec 3.2.*) inhibitors (aka ec 3.2.* (glycosylase) inhibitor)
H: ec 3.1.1.3 inhibitor (aka ec 3.1.1.3 (triacylglycerol lipase) inhibitor)
I: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
J: s-adenosyl-l-methionine:(s)-7,8,13,14-tetrahydroprotoberberine cis-n-methyltransferase inhibitor (aka ec 2.1.1.122 [(s)-tetrahydroprotoberberine n-methyltransferase] inhibitor)
K: None of the above. | K |
<Instruct>: Given the context 'Ink and casting dye injections
Embryos (E10.0 – E13.0) were dissected and placed in ice cold PBS (n≥3 per genotype in each time point).', select the correct biomedical concept corresponding to 'dye'. Answer using one of the provided options. | <Options>: A: calpain-2 (ec 3.4.22.53) inhibitor (aka ec 3.4.22.53 (calpain-2) inhibitor)
B: hemiterpenoid indole alkaloids (aka hemiterpenoid indole alkaloid)
C: ergot alkaloid (ergot alkaloids) (aka ergot alkaloid)
D: acid sphingomyelinase inhibitor (aka ec 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor)
E: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
F: inhibitor of phosphoric monoester hydrolase (ec 3.1.3.*) (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
G: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
H: ec 3.1.4.53 inhibitor (aka ec 3.1.4.53 (3',5'-cyclic-amp phosphodiesterase) inhibitor)
I: fructose 1,6-bisphosphatase inhibitor (aka ec 3.1.3.11 (fructose-bisphosphatase) inhibitor)
J: None of the above. | J |
<Instruct>: Given the context 'Using a pulled glass pipette, India ink or Yellow casting dye (Connecticut Valley Biological Supply) was injected into the ventricles until ink/dye penetrated small vessels.', select the correct biomedical concept corresponding to 'dye'. Answer using one of the provided options. | <Options>: A: inhibitor of phosphoric monoester hydrolase (ec 3.1.3.*) (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
B: hemiterpenoid indole alkaloids (aka hemiterpenoid indole alkaloid)
C: fructose 1,6-bisphosphatase inhibitor (aka ec 3.1.3.11 (fructose-bisphosphatase) inhibitor)
D: ec 3.1.4.12 inhibitor (aka ec 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor)
E: ec 3.1.4.53 inhibitor (aka ec 3.1.4.53 (3',5'-cyclic-amp phosphodiesterase) inhibitor)
F: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
G: ec 3.4.22.53 inhibitors (aka ec 3.4.22.53 (calpain-2) inhibitor)
H: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
I: ergot alkaloid (ergot alkaloids) (aka ergot alkaloid)
J: None of the above. | J |
<Instruct>: Given the context 'Using a pulled glass pipette, India ink or Yellow casting dye (Connecticut Valley Biological Supply) was injected into the ventricles until ink/dye penetrated small vessels.', select the correct biomedical concept corresponding to 'dye'. Answer using one of the provided options. | <Options>: A: ec 3.1.4.53 inhibitor (aka ec 3.1.4.53 (3',5'-cyclic-amp phosphodiesterase) inhibitor)
B: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
C: milli-calpain inhibitors (aka ec 3.4.22.53 (calpain-2) inhibitor)
D: smase inhibitors (aka ec 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor)
E: fructose 1,6-bisphosphatase inhibitor (aka ec 3.1.3.11 (fructose-bisphosphatase) inhibitor)
F: hemiterpenoid indole alkaloids (aka hemiterpenoid indole alkaloid)
G: ergot alkaloid (ergot alkaloids) (aka ergot alkaloid)
H: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
I: inhibitor of phosphoric monoester hydrolase (ec 3.1.3.*) (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
J: None of the above. | J |
<Instruct>: Given the context 'Embryos were postfixed in 10% buffered formalin for 12 hours, dehydrated and cleared in benzylbenzoate: benzyl alcohol (2:1v/v).
', select the correct biomedical concept corresponding to 'benzylbenzoate'. Answer using one of the provided options. | <Options>: A: 1-naphthylacetic acid (alpha-naphthaleneacetic acid) (aka 1-naphthylacetic acid)
B: ortho-iodylbenzoic acid (oc(=o)c1ccccc1i(=o)=o) (aka ortho-iodylbenzoic acid)
C: 4,4-dimethylbutanoate (aka isocaproate)
D: 3-oh-c12:0(1-) (aka 3-hydroxylaurate)
E: c23h32bn3o5 (aka (1r)-3-methyl-1-{[n-(morpholin-4-ylcarbonyl)-3-(1-naphthyl)-d-alanyl]amino}butylboronic acid)
F: [nh3+]ccop([o-])(=o)oc[c@h](o)coc=c[*] (aka 1-o-(alk-1-enyl)-sn-glycero-3-phosphoethanolamine zwitterion)
G: [h][c@@]12cc[c@@h](c)[c@@]1([h])[c@h](oc(=o)\c=c\c1ccccc1)[c@@]1(c[c@@h](oc(=o)co)[c@@]2(c)o1)c(c)c (aka englerin a)
H: 3,12-dihydroxylaurate (beta,omega-dihydroxydodecanoate) (aka 3,12-dihydroxylaurate)
I: oc(=o)c1ccccc1i=o (aka ortho-iodosylbenzoic acid)
J: [h][c@]1(o[c@@](o)(c[c@h](o)[c@h]1n)c(o)=o)[c@h](n)[c@@h](c)o (aka legionaminic acid)
K: None of the above. | K |
<Instruct>: Given the context 'Embryos were postfixed in 10% buffered formalin for 12 hours, dehydrated and cleared in benzylbenzoate: benzyl alcohol (2:1v/v).
', select the correct biomedical concept corresponding to 'benzyl alcohol'. Answer using one of the provided options. | <Options>: A: c19h21no4 (aka 3-acetylmorphine)
B: c8h14o3 (aka (1-hydroxycyclohexyl)acetic acid)
C: naphthylacetic acid (naphthalenylacetic acid) (aka naphthylacetic acid)
D: c2h3o2 (aka carboxymethyl group)
E: peroxy acids (aka peroxy acid)
F: ch3-co-cl (aka acetyl chloride)
G: None of the above. | G |
<Instruct>: Given the context 'Embryos were postfixed in 10% buffered formalin for 12 hours, dehydrated and cleared in benzylbenzoate: benzyl alcohol (2:1v/v).
', select the correct biomedical concept corresponding to 'formalin'. Answer using one of the provided options. | <Options>: A: propanals
B: sarmentogenin (c[c@]12c[c@@h](o)[c@h]3[c@@h](cc[c@@h]4c[c@@h](o)cc[c@]34c)[c@@]1(o)cc[c@@h]2c1=cc(=o)oc1) (aka sarmentogenin)
C: 3-[(4-[(3-oxopropyl)amino]butyl)amino]propionaldehyde
D: [h]c(=cc=o)c(o)ccccc (aka 4-hydroxynon-2-enal)
E: 7-deazaadenosine-7-carboxamide (aka sangivamycin)
F: 2-(6-amino-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol (aka adenine arabinoside)
G: 2-phenylbutanoic acid (aka 2-phenylbutyric acid)
H: lactaldehyde (2-hydroxypropionaldehyde) (aka lactaldehyde)
I: np(=o)(occc=o)n(cccl)cccl (aka aldophosphamide)
J: beta-aminopropion aldehyde (aka 3-aminopropanal)
K: None of the above. | K |
<Instruct>: Given the context 'A recent report disclosed an additional problem: the Hygromycin–Thymidine Kinase fusion gene used most frequently for positive/negative selection in RMCE, leads to mouse sterility, so that exchanges can only be performed in ES cells (16).
', select the correct biomedical concept corresponding to 'hygromycin'. Answer using one of the provided options. | <Options>: A: cc(c)=ccc1c(o)cc2oc3c=c(o)c(=o)c(cc=c(c)c)(cc=c(c)c)c3c(=o)c2c1o (aka allanxanthone c)
B: oc1ccc(cc1)\c=c\c=c\c=c\c(=o)c1ccc(o)cc1 (aka 1,7-bis-(4-hydroxyphenyl)-2,4,6-heptatrienone)
C: cyclo-[d-pen(2,5)]-enkephalin (aka dpdpe)
D: 1-desgalloyleugeniin (aka tellimagrandin i)
E: alpha-l-rhap-(1->3)-beta-d-glcp (c[c@@h]1o[c@@h](o[c@@h]2[c@@h](o)[c@h](o)o[c@h](co)[c@h]2o)[c@h](o)[c@h](o)[c@h]1o) (aka alpha-l-rhap-(1->3)-beta-d-glcp)
F: sesquiterpene (sesquiterpenes) (aka sesquiterpene)
G: coc1c(c)c(o)cc2c=cc3c(o)c(cc=c(c)c)ccc3oc12 (aka bauhinoxepin b)
H: c3h2f6o (aka (s)-desflurane)
I: ile (aka l-isoleucine) (aka l-isoleucine)
J: p-isopropyltoluene (aka p-cymene)
K: None of the above. | K |
<Instruct>: Given the context 'Cell culture conditions
Primary MEFs, isolated from 13.5 day embryos, were cultured in DMEM with 15% FBS, 100 mM BME, 2 mM l-glutamine and antibiotics.', select the correct biomedical concept corresponding to 'antibiotics'. Answer using one of the provided options. | <Options>: A: [h][c@@](o)(co)[c@@]([h])(o)[c@@]([h])(o)[c@]([h])(o)c=o (aka d-altrose)
B: alpha-d-allopyranose (aka alpha-d-allose)
C: tulio (aka thulium atom)
D: chemical substance (chemische substanz) (aka chemical substance)
E: [pa] (aka protactinium atom) (aka protactinium atom)
F: scandium group element atom (scandium group elements) (aka scandium group element atom)
G: platinum(ii) di-chloride (aka platinum dichloride)
H: trans-diamminedichloroplatinum(ii) (aka transplatin)
I: ytterbium (70yb (aka ytterbium))
J: pure substance (reine substanz) (aka pure substance)
K: None of the above. | K |
<Instruct>: Given the context '129/SvJae ES cells were grown in the same medium supplemented with 1000 U/ml ESGRO (Chemicon), on a layer of mitomycin C-treated SNLPuro-7/4 feeders (kind gift of A. Bradley).', select the correct biomedical concept corresponding to 'mitomycin c'. Answer using one of the provided options. | <Options>: A: apigenin-7-olate (5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-7-olate) (aka apigenin-7-olate)
B: 3,6-dioxocyclohexa-1,4-dien-1-olate (2-hydroxy-1,4-benzoquinone) (aka 3,6-dioxocyclohexa-1,4-dien-1-olate)
C: c27h42o3 (aka delta(4)-dafachronic acid)
D: (25r)-delta(4)-dafachronic acid ([h][c@@]1(cc[c@@]2([h])[c@]3([h])ccc4=cc(=o)cc[c@]4(c)[c@@]3([h])cc[c@]12c)[c@h](c)ccc[c@@h](c)c(o)=o) (aka (25r)-delta(4)-dafachronic acid)
E: c27h42o3 (aka (25s)-delta(4)-dafachronic acid)
F: dafachronic acids
G: None of the above. | G |
<Instruct>: Given the context 'Selections were performed with 2 μg/ml puromycin, 0.2 μM FIAU or 2 μM ganciclovir.
', select the correct biomedical concept corresponding to 'puromycin'. Answer using one of the provided options. | <Options>: A: c[c@h]1o[c@@h](oc(c)(c)[c@@h]2cc[c@]3(c2)[c@@h](c)cc(=o)c=c3c)[c@h](o)[c@@h](o)[c@h]1o (aka rel-(2r,5s,10s)-6,10-dimethyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]dec-6-en-8-one)
B: oc(=o)c1ccc2c(=o)oc3(c4cc(cl)c(o)cc4oc4cc(o)c(cl)cc34)c2c1 (aka 6-carboxy-2',7'-dichlorofluorescein)
C: c21h36o6 (aka rel-(2r,5s,7s,10s)-10-methyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]-6-methylenespiro[4.5]decan-7-ol)
D: n-(2-hydroxy-hexanoyl)-sphing-4-enine (aka n-(2-hydroxyhexanoyl)sphingosine)
E: c30h22o13 (aka manniflavanone)
F: c9h9n (aka 3-phenylpropionitrile)
G: [h][c@]1(o[c@@h](co)[c@h](o)[c@h]1o)o[c@h]1[c@h](o)[c@@h](o)[c@]([h])(o[c@h]2cc[c@@]3(c)[c@@]([h])(cc[c@]4(c)[c@]3([h])cc=c3[c@]5([h])cc(c)(c)cc[c@@]5(cc[c@@]43c)c(=o)o[c@@h]3o[c@h](co)[c@@h](o)[c@h](o)[c@h]3o)c2(c)c)o[c@@h]1c(=o)occcc (aka taibaienoside i)
H: c42h81no4 (aka n-[(15z)-2-hydroxytetracosenoyl]sphingosine)
I: rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one (c[c@h]1o[c@@h](oc(c)(c)[c@@h]2cc[c@]3(c2)[c@@h](c)ccc(=o)c3=c)[c@h](o)[c@@h](o)[c@h]1o) (aka rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one)
J: c48h76o18 (aka chikusetsusaponin-iv methyl ester)
K: None of the above. | K |
<Instruct>: Given the context 'Selections were performed with 2 μg/ml puromycin, 0.2 μM FIAU or 2 μM ganciclovir.
', select the correct biomedical concept corresponding to 'ganciclovir'. Answer using one of the provided options. | <Options>: A: 5alpha-androst-16-ene ([h][c@]12cccc[c@]1(c)[c@@]1([h])cc[c@]3(c)c=cc[c@@]3([h])[c@]1([h])cc2) (aka 5alpha-androst-16-ene)
B: n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide (aka finasteride)
C: c22h32o3 (aka 17beta-hydroxy-5alpha-androst-1-en-3-one propionate)
D: androstenone (aka 5alpha-androst-16-en-3-one)
E: oc1ccc(cc1)c1coc2cc(o)ccc2c1=o (aka dihydrodaidzein)
F: c19h32 (aka 5beta-androstane)
G: [h][c@@]12ccc3cccc[c@]3(c)[c@@]1([h])cc[c@]1(c)c=cc[c@@]21[h] (aka androst-16-ene)
H: None of the above. | H |
<Instruct>: Given the context 'Targeting/genotyping of the RMCE-ready locus
29/SvJae ES cells were electroporated with the Flox construct linearized with PmeI, and puromycin resistant clones were analyzed as described (Figure 2).', select the correct biomedical concept corresponding to 'puromycin'. Answer using one of the provided options. | <Options>: A: c21h36o6 (aka rel-(2r,5s,7s,10s)-10-methyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]-6-methylenespiro[4.5]decan-7-ol)
B: c30h22o13 (aka manniflavanone)
C: c48h76o18 (aka chikusetsusaponin-iv methyl ester)
D: [h][c@]1(o[c@@h](co)[c@h](o)[c@h]1o)o[c@h]1[c@h](o)[c@@h](o)[c@]([h])(o[c@h]2cc[c@@]3(c)[c@@]([h])(cc[c@]4(c)[c@]3([h])cc=c3[c@]5([h])cc(c)(c)cc[c@@]5(cc[c@@]43c)c(=o)o[c@@h]3o[c@h](co)[c@@h](o)[c@h](o)[c@h]3o)c2(c)c)o[c@@h]1c(=o)occcc (aka taibaienoside i)
E: rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one (c[c@h]1o[c@@h](oc(c)(c)[c@@h]2cc[c@]3(c2)[c@@h](c)ccc(=o)c3=c)[c@h](o)[c@@h](o)[c@h]1o) (aka rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one)
F: c21h34o6 (aka rel-(2r,5s,10s)-6,10-dimethyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]dec-6-en-8-one)
G: c42h81no4 (aka n-[(15z)-2-hydroxytetracosenoyl]sphingosine)
H: ccccccccccccc\c=c\[c@@h](o)[c@h](co)nc(=o)c(o)cccc (aka n-(2-hydroxyhexanoyl)sphingosine)
I: c9h9n (aka 3-phenylpropionitrile)
J: oc(=o)c1ccc2c(=o)oc3(c4cc(cl)c(o)cc4oc4cc(o)c(cl)cc34)c2c1 (aka 6-carboxy-2',7'-dichlorofluorescein)
K: None of the above. | K |
<Instruct>: Given the context 'Performing RMCE in ES cells
A total of 8 × 105 p53RMCE/+ ES cells were grown without puromycin for 12 h, electroporated with 15 μg CMV-Cre plasmid (pOG231) and 200 μg of the exchange construct, and plated in T25 flasks at 105 cells per flask.', select the correct biomedical concept corresponding to 'puromycin'. Answer using one of the provided options. | <Options>: A: rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one (c[c@h]1o[c@@h](oc(c)(c)[c@@h]2cc[c@]3(c2)[c@@h](c)ccc(=o)c3=c)[c@h](o)[c@@h](o)[c@h]1o) (aka rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one)
B: c21h34o6 (aka rel-(2r,5s,10s)-6,10-dimethyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]dec-6-en-8-one)
C: c48h76o18 (aka chikusetsusaponin-iv methyl ester)
D: c9h9n (aka 3-phenylpropionitrile)
E: c[c@h]1o[c@@h](oc(c)(c)[c@@h]2cc[c@]3(c2)[c@@h](c)ccc=c3c)[c@h](o)[c@@h](o)[c@h]1o (aka hinesol beta-d-fucopyranoside, (rel)-)
F: 2-oh-c24 :1(omega-9) ceramide (aka n-[(15z)-2-hydroxytetracosenoyl]sphingosine)
G: [h][c@]1(o[c@@h](co)[c@h](o)[c@h]1o)o[c@h]1[c@h](o)[c@@h](o)[c@]([h])(o[c@h]2cc[c@@]3(c)[c@@]([h])(cc[c@]4(c)[c@]3([h])cc=c3[c@]5([h])cc(c)(c)cc[c@@]5(cc[c@@]43c)c(=o)o[c@@h]3o[c@h](co)[c@@h](o)[c@h](o)[c@h]3o)c2(c)c)o[c@@h]1c(=o)occcc (aka taibaienoside i)
H: c30h22o13 (aka manniflavanone)
I: c21h36o6 (aka rel-(2r,5s,7s,10s)-10-methyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]-6-methylenespiro[4.5]decan-7-ol)
J: n-(2-hydroxy-hexanoyl)-sphing-4-enine (aka n-(2-hydroxyhexanoyl)sphingosine)
K: None of the above. | K |
<Instruct>: Given the context 'Performing RMCE in MEFs
A total of 106 p53RMCE/− MEFs cells were grown without puromycin for 12 h, electroporated with 3 μg pOG231 and 30 μg exchange construct, and plated in a single 10 cm-dish, grown for 3 days then split in several dishes at 105 cells per dish.', select the correct biomedical concept corresponding to 'puromycin'. Answer using one of the provided options. | <Options>: A: c9h9n (aka 3-phenylpropionitrile)
B: c21h36o6 (aka rel-(2r,5s,7s,10s)-10-methyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]-6-methylenespiro[4.5]decan-7-ol)
C: n-(2-hydroxyhexanoyl)sphingosine (n-[(2s,3r,4e)-1,3-dihydroxyoctadec-4-en-2-yl]-2-hydroxyhexanamide) (aka n-(2-hydroxyhexanoyl)sphingosine)
D: rel-(2r,5s,10s)-6,10-dimethyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]dec-6-ene (aka hinesol beta-d-fucopyranoside, (rel)-)
E: c30h22o13 (aka manniflavanone)
F: c21h10cl2o7 (aka 6-carboxy-2',7'-dichlorofluorescein)
G: c21h34o6 (aka rel-(2r,5s,10s)-6,10-dimethyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]dec-6-en-8-one)
H: 2-oh-c24 :1(omega-9) ceramide (aka n-[(15z)-2-hydroxytetracosenoyl]sphingosine)
I: c48h76o18 (aka chikusetsusaponin-iv methyl ester)
J: rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one (c[c@h]1o[c@@h](oc(c)(c)[c@@h]2cc[c@]3(c2)[c@@h](c)ccc(=o)c3=c)[c@h](o)[c@@h](o)[c@h]1o) (aka rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one)
K: None of the above. | K |
<Instruct>: Given the context 'FIAU or ganciclovir was added to the medium 4 days after electroporation, for 3–4 days.', select the correct biomedical concept corresponding to 'ganciclovir'. Answer using one of the provided options. | <Options>: A: n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide (aka finasteride)
B: c19h30 (aka 5alpha-androst-16-ene)
C: (+/-)-dihydrodaidzein (aka dihydrodaidzein)
D: [h][c@@]12ccc3cccc[c@]3(c)[c@@]1([h])cc[c@]1(c)c=cc[c@@]21[h] (aka androst-16-ene)
E: c19h32 (aka 5beta-androstane)
F: c22h32o3 (aka 17beta-hydroxy-5alpha-androst-1-en-3-one propionate)
G: c19h28o (aka 5alpha-androst-16-en-3-one)
H: None of the above. | H |
<Instruct>: Given the context 'Western-blots
Cells, untreated or treated for 24 h with 0.5 μg/ml adriamycin, were lysed on the dish in a buffer consisting of 50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, 1 mM sodium vanadate, 10 mM NaF and Complete Mini Protease Inhibitors (Roche Diagnostics) at 4°C for 30 min. Lysates were scraped, then spun at 6000× g at 4°C for 10 min. Protein concentration in the supernatant was determined using the Bio-Rad DC protein assay.', select the correct biomedical concept corresponding to 'tris'. Answer using one of the provided options. | <Options>: A: o[c@h]1[c@@h](o)[c@@h](o[c@@h]1cop(o)(o)=o)n1ccc(=n)c(c1)c(o)=o (aka clitidine 5'-phosphate)
B: c5h7no2 (aka l-glutamoyl group)
C: l-glutam-5-yl (aka l-gamma-glutamyl group)
D: o-decadienoylcarnitine (c[n+](c)(c)cc(cc([o-])=o)oc([*])=o) (aka o-decadienoylcarnitine)
E: vanadium(2+), ion (aka vanadium(2+))
F: l-glutaminsaeure (aka l-glutamic acid)
G: n-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-l-glutamic acid (aka methotrexate)
H: None of the above. | H |
<Instruct>: Given the context 'Western-blots
Cells, untreated or treated for 24 h with 0.5 μg/ml adriamycin, were lysed on the dish in a buffer consisting of 50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, 1 mM sodium vanadate, 10 mM NaF and Complete Mini Protease Inhibitors (Roche Diagnostics) at 4°C for 30 min. Lysates were scraped, then spun at 6000× g at 4°C for 10 min. Protein concentration in the supernatant was determined using the Bio-Rad DC protein assay.', select the correct biomedical concept corresponding to 'nacl'. Answer using one of the provided options. | <Options>: A: bile acid (aka bile salt)
B: alkali metal cation (alkali metal cations) (aka alkali metal cation)
C: c4h3auna2o4s (aka disodium aurothiomalate)
D: metal cations (aka metal cation)
E: [na+].nc1nc2n([c@@h]3o[c@@h]4cop([o-])(=o)o[c@h]4[c@h]3o)c(br)nc2c(=o)[nh]1 (aka sodium 8-bromo-3',5'-cyclic gmp)
F: glycocholate sodium (aka sodium glycocholate)
G: chlorides (aka chloride salt)
H: salt (aka sodium chloride) (aka sodium chloride)
I: None of the above. | H |
<Instruct>: Given the context 'Western-blots
Cells, untreated or treated for 24 h with 0.5 μg/ml adriamycin, were lysed on the dish in a buffer consisting of 50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, 1 mM sodium vanadate, 10 mM NaF and Complete Mini Protease Inhibitors (Roche Diagnostics) at 4°C for 30 min. Lysates were scraped, then spun at 6000× g at 4°C for 10 min. Protein concentration in the supernatant was determined using the Bio-Rad DC protein assay.', select the correct biomedical concept corresponding to 'pmsf'. Answer using one of the provided options. | <Options>: A: n-acyl-l-alanine (c[c@h](nc([*])=o)c(o)=o) (aka n-acyl-l-alanine)
B: n-acylimines (aka n-acylimine)
C: d-q-r (aka asp-gln-arg)
D: c3h6o2 (aka methyl acetate)
E: oc1ccc(cc1)n=c1c=cc(=o)c=c1 (aka indophenol)
F: phospho(1-aminoethyl)(2-carboxypropyl)phosphinic acid (c[c@@h](n)p(=o)(c[c@h](c)c(o)=o)op(o)(o)=o) (aka phospho(1-aminoethyl)(2-carboxypropyl)phosphinic acid)
G: l-alanylglycyl-l-tyrosine (aka ala-gly-tyr)
H: ophiobolin a ([h][c@@]1(c[c@h](c)[c@]2(cc[c@]3(c)c[c@@]4([h])[c@]([h])(c(=o)c[c@@]4(c)o)\c(c=o)=c/c[c@@]23[h])o1)c=c(c)c) (aka ophiobolin a)
I: hscn (aka thiocyanic acid) (aka thiocyanic acid)
J: (3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxododecahydro-1h-benzo[f]chromen-5-yl acetate (aka forskolin)
K: None of the above. | K |
<Instruct>: Given the context 'Western-blots
Cells, untreated or treated for 24 h with 0.5 μg/ml adriamycin, were lysed on the dish in a buffer consisting of 50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, 1 mM sodium vanadate, 10 mM NaF and Complete Mini Protease Inhibitors (Roche Diagnostics) at 4°C for 30 min. Lysates were scraped, then spun at 6000× g at 4°C for 10 min. Protein concentration in the supernatant was determined using the Bio-Rad DC protein assay.', select the correct biomedical concept corresponding to 'sodium vanadate'. Answer using one of the provided options. | <Options>: A: atto 495 biotin derivative (aka atto 495-7)
B: disodium monohydrogen phosphate (aka disodium hydrogenphosphate)
C: c22h27cln2o7 (aka atto 520-2)
D: sodium phosphate, monobasic (aka sodium dihydrogenphosphate)
E: atto 495 maleimide (aka atto 495-4)
F: atto 520 succinimidyl ester (aka atto 520-3)
G: None of the above. | G |
<Instruct>: Given the context 'Western-blots
Cells, untreated or treated for 24 h with 0.5 μg/ml adriamycin, were lysed on the dish in a buffer consisting of 50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, 1 mM sodium vanadate, 10 mM NaF and Complete Mini Protease Inhibitors (Roche Diagnostics) at 4°C for 30 min. Lysates were scraped, then spun at 6000× g at 4°C for 10 min. Protein concentration in the supernatant was determined using the Bio-Rad DC protein assay.', select the correct biomedical concept corresponding to 'naf'. Answer using one of the provided options. | <Options>: A: potassium fluorure (aka potassium fluoride)
B: fna (aka sodium fluoride) (aka sodium fluoride)
C: o[c@@h]1[c@@h](coc(=o)c2cc(o)c(o)c(o)c2)o[c@@h](oc2cc(o)c3c(=o)c[c@h](oc3c2)c2ccc(o)cc2)[c@h](o)[c@h]1o (aka prunin 6''-o-gallate)
D: fluoride salt (fluoride salts) (aka fluoride salt)
E: oc1cc(o)c2c[c@@h](oc(=o)c3cc(o)c(o)c(o)c3)[c@h](oc2c1)c1ccc(o)c(o)c1 (aka (-)-epicatechin-3-o-gallate)
F: maleate (aka maleate(2-))
G: f(-) (aka fluoride) (aka fluoride)
H: None of the above. | B |
<Instruct>: Given the context 'Western-blots
Cells, untreated or treated for 24 h with 0.5 μg/ml adriamycin, were lysed on the dish in a buffer consisting of 50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, 1 mM sodium vanadate, 10 mM NaF and Complete Mini Protease Inhibitors (Roche Diagnostics) at 4°C for 30 min. Lysates were scraped, then spun at 6000× g at 4°C for 10 min. Protein concentration in the supernatant was determined using the Bio-Rad DC protein assay.', select the correct biomedical concept corresponding to 'nonidet p-40'. Answer using one of the provided options. | <Options>: A: c17h23no (aka levorphanol)
B: c18h20n2o3 (aka phe-phe)
C: 4-o-prenyl-l-tyrosine zwitterion (aka 4-o-dimethylallyl-l-tyrosine zwitterion)
D: c[c@h](o)[c@h](c)[c@h]([nh3+])c([o-])=o (aka (4s)-4-hydroxy-l-isoleucine zwitterion)
E: cn1cc[c@@]23[c@h]4oc5c2c(c[c@@h]1[c@]3(o)ccc4=o)ccc5o (aka oxymorphone)
F: cc1cc(c[c@h]([nh3+])c([o-])=o)cc(o)c1o (aka 5-hydroxy-3-methyl-l-tyrosine zwitterion)
G: hexatriacontapentaenoic acids (aka hexatriacontapentaenoic acid)
H: [h][c@@](coc([*])=o)(cop([o-])(=o)occ[n+](c)(c)c)oc([*])=o (aka phosphatidylcholine 48:2)
I: c11h12o6 (aka eucomic acid, (-)-)
J: (3s,8as)-3-(1h-indol-3-ylmethyl)hexahydropyrrolo[1,2-a]pyrazine-1,4-dione (aka brevianamide f)
K: None of the above. | K |
<Instruct>: Given the context 'Western-blots
Cells, untreated or treated for 24 h with 0.5 μg/ml adriamycin, were lysed on the dish in a buffer consisting of 50 mM Tris (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet P-40, 1 mM PMSF, 1 mM sodium vanadate, 10 mM NaF and Complete Mini Protease Inhibitors (Roche Diagnostics) at 4°C for 30 min. Lysates were scraped, then spun at 6000× g at 4°C for 10 min. Protein concentration in the supernatant was determined using the Bio-Rad DC protein assay.', select the correct biomedical concept corresponding to 'adriamycin'. Answer using one of the provided options. | <Options>: A: beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcpo[ch2]3nh2 (c[c@@h]1o[c@@h](o[c@h]2[c@h](o)[c@@h](co)o[c@@h](occcn)[c@@h]2o)[c@h](o)[c@h](o[c@@h]2o[c@h](co)[c@@h](o)[c@h](o[c@@h]3o[c@h](co)[c@@h](o)[c@h](o)[c@@h]3o)[c@@h]2o)[c@h]1o) (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcpo[ch2]3nh2)
B: n-methyl-3-phenothiazinylacetic acid (aka metiazinic acid)
C: erythromycin c (aka erythromycin c(1+))
D: c[c@@h](o[c@h]1occn(cc2n[nh]c(=o)[nh]2)[c@h]1c1ccc(f)cc1)c1cc(cc(c1)c(f)(f)f)c(f)(f)f (aka aprepitant)
E: methyl (alphae)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]-alpha-(methoxymethylene)benzeneacetate (aka flufenoxystrobin)
F: 17-hydroxylupaninium (aka 17-hydroxylupanine(1+))
G: procure (aka triflumizole)
H: [h][c@@]12cc[c@@]3([h])[c@]4([h])cc[c@]([h])(c(=o)nc5cc(ccc5c(f)(f)f)c(f)(f)f)[c@@]4(c)cc[c@]3([h])[c@@]1(c)c=cc(=o)n2 (aka dutasteride)
I: phcf3 (aka (trifluoromethyl)benzene)
J: beta-d-mannopyranosyl-(1->3)-beta-d-mannopyranosyl-(1->3)-6-deoxy-alpha-l-mannopyranosyl-(1->3)-beta-d-glucopyranosyl (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcp-yl group)
K: None of the above. | K |
<Instruct>: Given the context 'Lysates were separated on single percentage SDS/PAGE gels, then electrophoretically transferred to poly(vinylidene difluoride), using standard procedures.', select the correct biomedical concept corresponding to 'sds'. Answer using one of the provided options. | <Options>: A: amifostina (aka amifostine)
B: beta-mercaptoethanol (aka mercaptoethanol)
C: methyl 2-hydroxyethyl sulfide (aka 2-methylthioethanol)
D: (1s-cis)-triphosphoric acid, p-((4-(2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)-2-cyclopenten-1-yl)methyl) ester (aka carbovir triphosphate)
E: (s)-sulforaphane (1-isothiocyanato-4-[(s)-methylsulfinyl]butane) (aka (s)-sulforaphane)
F: 2-{[(4-amino-2-methylpyrimidin-5-yl)methyl]amino}propane-1-thiol (aka (2s)-2-{[(4-amino-2-methylpyrimidin-5-yl)methyl]amino}propane-1-thiol)
G: cystamine (beta,beta'-diaminodiethyl disulfide) (aka cystamine)
H: n-acetyl-alpha-d-mannosaminyl-(1-p-6)-n-acetyl-alpha-d-mannosaminyl-(1-p-6)-n-acetyl-alpha-d-mannosamine (aka alpha-d-manpac-(1-p-6)-alpha-d-manpac-(1-p-6)-alpha-d-manpac)
I: s-(2-aminoethyl) dihydrogen phosphorothioate (aka cysteamine s-phosphate)
J: c18h20o9 (aka rubinaphthin a methyl ester)
K: None of the above. | K |
<Instruct>: Given the context 'Lysates were separated on single percentage SDS/PAGE gels, then electrophoretically transferred to poly(vinylidene difluoride), using standard procedures.', select the correct biomedical concept corresponding to 'poly(vinylidene difluoride'. Answer using one of the provided options. | <Options>: A: ch2=c=c=ch2 (aka butatriene)
B: c30h28o10 (aka lignin cw compound-1009)
C: cerium coordination entities (aka cerium coordination entity)
D: lignin cw compound-1028 (cc(=o)oc=1c=cc(=cc1oc)c(c(co)oc2=cc=cc=c2oc)=o) (aka lignin cw compound-1028)
E: c18h18o6 (aka lignin cw compound-1027)
F: c31h30o11 (aka lignin cw compound-1010)
G: cerium(iii) chloride (aka cerium trichloride)
H: cc(c=1c=cc(=c(c1)oc)occ(c=2c=cc(=c(c2)oc)oc)=o)=o (aka lignin cw compound-146)
I: None of the above. | I |
<Instruct>: Given the context 'Blots were incubated in 5% non-fat dried milk in TBST (0.02 M Tris, pH 7.6/0.35 M NaCl/0.1% Tween-20) for 1 h at room temperature before probing with primary antibodies against p53 (CM-5, Novacastra) and -actin (Sigma).', select the correct biomedical concept corresponding to 'tris'. Answer using one of the provided options. | <Options>: A: l-glutamoyl group ((2s)-2-aminobutanedioyl) (aka l-glutamoyl group)
B: c5h8no3 (aka l-gamma-glutamyl group)
C: v (aka vanadium(2+)) (aka vanadium(2+))
D: n-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-l-glutamic acid (aka methotrexate)
E: l-glutaminsaeure (aka l-glutamic acid)
F: o[c@h]1[c@@h](o)[c@@h](o[c@@h]1cop(o)(o)=o)n1ccc(=n)c(c1)c(o)=o (aka clitidine 5'-phosphate)
G: o-decadienoylcarnitine (c[n+](c)(c)cc(cc([o-])=o)oc([*])=o) (aka o-decadienoylcarnitine)
H: None of the above. | H |
<Instruct>: Given the context 'Blots were incubated in 5% non-fat dried milk in TBST (0.02 M Tris, pH 7.6/0.35 M NaCl/0.1% Tween-20) for 1 h at room temperature before probing with primary antibodies against p53 (CM-5, Novacastra) and -actin (Sigma).', select the correct biomedical concept corresponding to 'nacl'. Answer using one of the provided options. | <Options>: A: glycocholate sodium (aka sodium glycocholate)
B: c4h3auna2o4s (aka disodium aurothiomalate)
C: metal cations (aka metal cation)
D: sodium chloride (salt (aka sodium chloride))
E: chlorides (aka chloride salt)
F: alkali metal cation (alkali metal cations) (aka alkali metal cation)
G: bile acid (aka bile salt)
H: [na+].nc1nc2n([c@@h]3o[c@@h]4cop([o-])(=o)o[c@h]4[c@h]3o)c(br)nc2c(=o)[nh]1 (aka sodium 8-bromo-3',5'-cyclic gmp)
I: None of the above. | D |
<Instruct>: Given the context 'Blots were incubated in 5% non-fat dried milk in TBST (0.02 M Tris, pH 7.6/0.35 M NaCl/0.1% Tween-20) for 1 h at room temperature before probing with primary antibodies against p53 (CM-5, Novacastra) and -actin (Sigma).', select the correct biomedical concept corresponding to 'tween-20'. Answer using one of the provided options. | <Options>: A: resolvin d2 (cc\c=c/c[c@h](o)[c@h](o)\c=c\c=c\c=c/c=c/[c@@h](o)c\c=c/ccc(o)=o) (aka resolvin d2)
B: 7s,8r,17s-trihydroxydocosa-4z,9e,11e,13z,15e,19z-hexaenoic acid (aka resolvin d1)
C: 36:6(omega3) (aka (18z,21z,24z,27z,30z,33z)-hexatriacontahexaenoic acid)
D: 58-carbamimidamido-13,15,33,35,39,41,43,47,49,53,55-undecahydroxy-2,12,14,30-tetramethyl-31-oxo-29-(sulfooxy)octapentaconta-2,4,6,10,16,18,20,22,24,26,36,44,50-tridecaenoic acid (aka clethramycin)
E: 38:4(23z,26z,29z,32z) (aka (23z,26z,29z,32z)-octatriacontatetraenoic acid)
F: 36:5(21z,24z,27z,30z,33z) (aka (21z,24z,27z,30z,33z)-hexatriacontapentaenoic acid)
G: 13,16,19-docosatrienoic acid ((13e,16e,19e)-docosa-13,16,19-trienoic acid) (aka 13,16,19-docosatrienoic acid)
H: c34h58o2 (aka (19z,22z,25z,28z,31z)-tetratriacontapentaenoic acid)
I: tetratriacontahexaenoic acid (tetratriacontahexaenoic acids) (aka tetratriacontahexaenoic acid)
J: hexatriacontapentaenoic acids (aka hexatriacontapentaenoic acid)
K: None of the above. | K |
<Instruct>: Given the context 'Flow cytometry
Log phase cells were irradiated at RT with a 60 Co γ-irradiator at doses of 6 or 12 Gy and incubated for 24 h. Cells were then pulse-labeled for 1 h with BrdU (10 μM), fixed in 70% ethanol, double-stained with FITC anti-BrdU and propidium iodide, then sorted by using a Becton Dickinson FACScan machine.', select the correct biomedical concept corresponding to 'ethanol'. Answer using one of the provided options. | <Options>: A: furadan (aka carbofuran)
B: benzyl {(1r)-3-oxo-1-phenyl-3-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)amino]propyl}carbamate ([h]sc1nnc(s1)n([h])c(=o)c([h])([h])[c@@]([h])(n([h])c(=o)oc([h])([h])c1c([h])c([h])c([h])c([h])c1[h])c1c([h])c([h])c([h])c([h])c1[h]) (aka benzyl {(1r)-3-oxo-1-phenyl-3-[(5-sulfanyl-1,3,4-thiadiazol-2-yl)amino]propyl}carbamate)
C: (5z,8z,11z,14z,17z)-19-hydroxyicosapentaenoic acid (aka 19-hepe)
D: c11h15no2 (aka trimethacarb)
E: physostigmine ((3as,8ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate) (aka physostigmine)
F: c11h15no2 (aka 2,3,5-trimethylphenyl methylcarbamate)
G: mf 268 (aka 5-o-[8-(cis-2,6-dimethylmorpholino)octylcarbamoyl]eseroline)
H: 2,3-dihydro-2,2-dimethyl-7-benzofuranyl 2,4-dimethyl-5-oxo-6-oxa-3-thia-2,4-diazadecanoate (aka furathiocarb)
I: 4alpha,14alpha-dimethyl-5alpha-ergosta-8,24(28)-dien-3beta-ol (aka obtusifoliol)
J: 5alpha-ergosta-7,22-diene-3beta,5-diol ([h][c@@]1(cc[c@@]2([h])c3=cc[c@@]4(o)c[c@@h](o)cc[c@]4(c)[c@@]3([h])cc[c@]12c)[c@h](c)\c=c\[c@h](c)c(c)c) (aka 5alpha-ergosta-7,22-diene-3beta,5-diol)
K: None of the above. | K |
<Instruct>: Given the context 'Flow cytometry
Log phase cells were irradiated at RT with a 60 Co γ-irradiator at doses of 6 or 12 Gy and incubated for 24 h. Cells were then pulse-labeled for 1 h with BrdU (10 μM), fixed in 70% ethanol, double-stained with FITC anti-BrdU and propidium iodide, then sorted by using a Becton Dickinson FACScan machine.', select the correct biomedical concept corresponding to 'fitc'. Answer using one of the provided options. | <Options>: A: (r)-piperidine-3-carboxylic acid zwitterion (aka (r)-nipecotic acid zwitterion)
B: (2s)-2-azaniumyl-3-chloropropanoate (aka 3-chloro-d-alanine zwitterion)
C: (2s)-pyrrolidinium-2-carboxylate (aka l-proline zwitterion)
D: glutathione amide disulfide (aka glutathione amide disulfide dizwitterion)
E: n-formyl-d-kynurenine zwitterion ((2r)-2-azaniumyl-4-(2-formamidophenyl)-4-oxobutanoate) (aka n-formyl-d-kynurenine zwitterion)
F: (2s)-2-azaniumyl-5-(n''-hydroxycarbamimidamido)pentanoate (aka n(5)-[amino(hydroxyimino)methyl]-l-ornithine zwitterion)
G: c5h9no3 (aka cis-3-hydroxy-l-proline zwitterion)
H: None of the above. | H |
<Instruct>: Given the context 'Flow cytometry
Log phase cells were irradiated at RT with a 60 Co γ-irradiator at doses of 6 or 12 Gy and incubated for 24 h. Cells were then pulse-labeled for 1 h with BrdU (10 μM), fixed in 70% ethanol, double-stained with FITC anti-BrdU and propidium iodide, then sorted by using a Becton Dickinson FACScan machine.', select the correct biomedical concept corresponding to 'brdu'. Answer using one of the provided options. | <Options>: A: c30h52o26 (aka maltopentaose)
B: c12h22o10 (aka beta-d-galactosyl-(1->4)-l-rhamnose)
C: mannooligosaccharide (mannosyloligosaccharides) (aka mannooligosaccharide)
D: alpha-l-rhap-(1->2)-alpha-l-rhap (c[c@@h]1o[c@@h](o)[c@h](o[c@@h]2o[c@@h](c)[c@h](o)[c@@h](o)[c@h]2o)[c@h](o)[c@h]1o) (aka alpha-l-rhap-(1->2)-alpha-l-rhap)
E: glycosylrhamnoses (aka glycosylrhamnose)
F: ec 2.1.1.72 [site-specific dna-methyltransferase (adenine-specific)] inhibitors (aka ec 2.1.1.72 [site-specific dna-methyltransferase (adenine-specific)] inhibitor)
G: cccccoc(=o)coc1cc(n2c(=o)c3=c(cccc3)c2=o)c(f)cc1cl (aka flumiclorac pentyl)
H: l-1,2:3,4-diepoxybutane (aka (s,s)-diepoxybutane)
I: None of the above. | I |
<Instruct>: Given the context 'Flow cytometry
Log phase cells were irradiated at RT with a 60 Co γ-irradiator at doses of 6 or 12 Gy and incubated for 24 h. Cells were then pulse-labeled for 1 h with BrdU (10 μM), fixed in 70% ethanol, double-stained with FITC anti-BrdU and propidium iodide, then sorted by using a Becton Dickinson FACScan machine.', select the correct biomedical concept corresponding to 'brdu'. Answer using one of the provided options. | <Options>: A: c12h22o10 (aka beta-d-galactosyl-(1->4)-l-rhamnose)
B: (2s,2's)-2,2'-bioxirane (aka (s,s)-diepoxybutane)
C: ec 2.1.1.72 [site-specific dna-methyltransferase (adenine-specific)] inhibitors (aka ec 2.1.1.72 [site-specific dna-methyltransferase (adenine-specific)] inhibitor)
D: mannooligosaccharide (mannosyloligosaccharides) (aka mannooligosaccharide)
E: cccccoc(=o)coc1cc(n2c(=o)c3=c(cccc3)c2=o)c(f)cc1cl (aka flumiclorac pentyl)
F: maltopentaose (oc[c@@h](o)[c@@h](o[c@h]1o[c@h](co)[c@@h](o[c@h]2o[c@h](co)[c@@h](o[c@h]3o[c@h](co)[c@@h](o[c@h]4o[c@h](co)[c@@h](o)[c@h](o)[c@h]4o)[c@h](o)[c@h]3o)[c@h](o)[c@h]2o)[c@h](o)[c@h]1o)[c@h](o)[c@@h](o)c=o) (aka maltopentaose)
G: glycosyl rhamnose (aka glycosylrhamnose)
H: 6-deoxy-2-o-(6-deoxy-alpha-l-mannopyranosyl)-alpha-l-mannopyranose (aka alpha-l-rhap-(1->2)-alpha-l-rhap)
I: None of the above. | I |
<Instruct>: Given the context 'Flow cytometry
Log phase cells were irradiated at RT with a 60 Co γ-irradiator at doses of 6 or 12 Gy and incubated for 24 h. Cells were then pulse-labeled for 1 h with BrdU (10 μM), fixed in 70% ethanol, double-stained with FITC anti-BrdU and propidium iodide, then sorted by using a Becton Dickinson FACScan machine.', select the correct biomedical concept corresponding to 'propidium iodide'. Answer using one of the provided options. | <Options>: A: 4,4'-methylenebis(3-hydroxynaphthalene-2-carboxylate) (aka pamoate(2-))
B: c4h4n2 (aka diazine)
C: c5h4o4 (aka itaconate(2-))
D: bromobenzoic acid (bromobenzoic acids) (aka bromobenzoic acid)
E: c12h15o10p (aka arbutin 6-phosphate(2-))
F: c7h7no5 (aka (2s,4s)-4-hydroxy-2,3,4,5-tetrahydrodipicolinate(2-))
G: [h][c@]12nc3nc(n)[nh]c(=o)c3n[c@@]1([h])c(s)=c([s-])[c@@h](cop([o-])(=o)op([o-])(=o)oc[c@h]1o[c@h]([c@h](o)[c@@h]1o)n1cnc3c1nc(n)[nh]c3=o)o2 (aka molybdopterin guanine dinucleotide(3-))
H: 1-[(4-chlorophenyl)(phenyl)methyl]-4-[2-(2-hydroxyethoxy)ethyl]piperazinediium 4,4'-methylenebis(3-hydroxynaphthalene-2-carboxylate) (aka hydroxyzine pamoate)
I: cc(=o)o[c@h]1cc2ccccc2n(c(n)=o)c2ccccc12 (aka eslicarbazepine acetate)
J: [o-]c(=o)cc([s-])c([o-])=o (aka thiomalate(3-))
K: None of the above. | K |
<Instruct>: Given the context 'The frequency of targeting was 4% (12/300 puromycin-resistant clones, analyzed by Southern blot and long-range PCR, Figure 2).
', select the correct biomedical concept corresponding to 'puromycin'. Answer using one of the provided options. | <Options>: A: c48h76o18 (aka chikusetsusaponin-iv methyl ester)
B: n-(2-hydroxyhexanoyl)sphingosine (n-[(2s,3r,4e)-1,3-dihydroxyoctadec-4-en-2-yl]-2-hydroxyhexanamide) (aka n-(2-hydroxyhexanoyl)sphingosine)
C: c42h81no4 (aka n-[(15z)-2-hydroxytetracosenoyl]sphingosine)
D: c21h36o6 (aka rel-(2r,5s,7s,10s)-10-methyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]-6-methylenespiro[4.5]decan-7-ol)
E: c[c@h]1o[c@@h](oc(c)(c)[c@@h]2cc[c@]3(c2)[c@@h](c)cc(=o)c=c3c)[c@h](o)[c@@h](o)[c@h]1o (aka rel-(2r,5s,10s)-6,10-dimethyl-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]dec-6-en-8-one)
F: phenylpropionitrile (aka 3-phenylpropionitrile)
G: [h][c@]1(o[c@@h](co)[c@h](o)[c@h]1o)o[c@h]1[c@h](o)[c@@h](o)[c@]([h])(o[c@h]2cc[c@@]3(c)[c@@]([h])(cc[c@]4(c)[c@]3([h])cc=c3[c@]5([h])cc(c)(c)cc[c@@]5(cc[c@@]43c)c(=o)o[c@@h]3o[c@h](co)[c@@h](o)[c@h](o)[c@h]3o)c2(c)c)o[c@@h]1c(=o)occcc (aka taibaienoside i)
H: c30h22o13 (aka manniflavanone)
I: rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one (c[c@h]1o[c@@h](oc(c)(c)[c@@h]2cc[c@]3(c2)[c@@h](c)ccc(=o)c3=c)[c@h](o)[c@@h](o)[c@h]1o) (aka rel-(2r,5s,10s)-10-methyl-6-methylene-2-[(1-methyl-1-beta-d-fucopyranosyloxy)ethyl]spiro[4.5]decan-8-one)
J: c21h10cl2o7 (aka 6-carboxy-2',7'-dichlorofluorescein)
K: None of the above. | K |
<Instruct>: Given the context 'Surprisingly, the fusion of GFP to p53 apparently altered p53 stability: steady-state levels of p53GFP were much higher than those of wild-type p53 (p53WT) in unstressed cells, and did not vary significantly after DNA damage, so that the levels for both p53WT and p53GFP were similar after adriamycin treatment (Figure 3A).
', select the correct biomedical concept corresponding to 'adriamycin'. Answer using one of the provided options. | <Options>: A: [h][c@@]12cc[c@@]3([h])[c@]4([h])cc[c@]([h])(c(=o)nc5cc(ccc5c(f)(f)f)c(f)(f)f)[c@@]4(c)cc[c@]3([h])[c@@]1(c)c=cc(=o)n2 (aka dutasteride)
B: methyl (alphae)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]-alpha-(methoxymethylene)benzeneacetate (aka flufenoxystrobin)
C: c7h5f3 (aka (trifluoromethyl)benzene)
D: beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcpo[ch2]3nh2 (c[c@@h]1o[c@@h](o[c@h]2[c@h](o)[c@@h](co)o[c@@h](occcn)[c@@h]2o)[c@h](o)[c@h](o[c@@h]2o[c@h](co)[c@@h](o)[c@h](o[c@@h]3o[c@h](co)[c@@h](o)[c@h](o)[c@@h]3o)[c@@h]2o)[c@h]1o) (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcpo[ch2]3nh2)
E: procure (aka triflumizole)
F: 17-hydroxylupaninium (aka 17-hydroxylupanine(1+))
G: erythromycin c cation (aka erythromycin c(1+))
H: c24h41o19 (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcp-yl group)
I: n-methyl-3-phenothiazinylacetic acid (aka metiazinic acid)
J: 5-{[(2r,3s)-2-{(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3h-1,2,4-triazol-3-one (aka aprepitant)
K: None of the above. | K |
<Instruct>: Given the context 'We first attempted RMCE in MEFs by electroporating p53RMCE/− MEFs with a Cre-expression plasmid and the p53GFP plasmid, followed by selection with FIAU or ganciclovir.', select the correct biomedical concept corresponding to 'ganciclovir'. Answer using one of the provided options. | <Options>: A: 5alpha-androst-16-ene ([h][c@]12cccc[c@]1(c)[c@@]1([h])cc[c@]3(c)c=cc[c@@]3([h])[c@]1([h])cc2) (aka 5alpha-androst-16-ene)
B: 7-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydro-4h-chromen-4-one (aka dihydrodaidzein)
C: c19h28o (aka 5alpha-androst-16-en-3-one)
D: androst-16-ene ([h][c@@]12ccc3cccc[c@]3(c)[c@@]1([h])cc[c@]1(c)c=cc[c@@]21[h]) (aka androst-16-ene)
E: c19h32 (aka 5beta-androstane)
F: finasterida (aka finasteride)
G: c22h32o3 (aka 17beta-hydroxy-5alpha-androst-1-en-3-one propionate)
H: None of the above. | H |
<Instruct>: Given the context 'The experiment was done without selection to enable observation of cells under conditions where a failure to proliferate would not derive from FIAU or ganciclovir toxicity but rather solely from the effects of p53GFP.', select the correct biomedical concept corresponding to 'ganciclovir'. Answer using one of the provided options. | <Options>: A: c22h32o3 (aka 17beta-hydroxy-5alpha-androst-1-en-3-one propionate)
B: androstenone (aka 5alpha-androst-16-en-3-one)
C: c19h30 (aka androst-16-ene)
D: n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide (aka finasteride)
E: 5alpha-androst-16-ene ([h][c@]12cccc[c@]1(c)[c@@]1([h])cc[c@]3(c)c=cc[c@@]3([h])[c@]1([h])cc2) (aka 5alpha-androst-16-ene)
F: 7,4'-dihydroxyisoflavanone (aka dihydrodaidzein)
G: c19h32 (aka 5beta-androstane)
H: None of the above. | H |
<Instruct>: Given the context 'The Flox targeting construct (below), the sequence which was verified before use (Materials and Methods), contains (i) a 3.4 kb-long 5′ homology region; (ii) 0.2 kb upstream of coding sequences, an EcoRI site and L3, a mutant loxP [loxP257, (14)]; (iii) p53 exons; (iv) 0.4 kb downstream, a puroΔTK fusion gene (puDTK) for positive/negative selection (21) and an inverted WT loxP (1L); (v) a 1.2 kb-long 3′ homology region and (vi) the diphteria α-toxin (DTA) gene for targeting enrichment.', select the correct biomedical concept corresponding to 'toxin'. Answer using one of the provided options. | <Options>: A: ec 3.5.2.* (non-peptide cyclic amide c-n hydrolase) inhibitors (aka ec 3.5.2.* (non-peptide cyclic amide c-n hydrolase) inhibitor)
B: atp-sensitive k(+) channel agonist (aka k-atp channel agonist)
C: oestrogen antagonist (aka estrogen antagonist)
D: butyrylcholine esterase inhibitor (aka ec 3.1.1.8 (cholinesterase) inhibitor)
E: yndase inhibitors (aka ec 3.5.1.19 (nicotinamidase) inhibitor)
F: None of the above. | F |
<Instruct>: Given the context 'In the representative western (right), cells from two independent p53+/GFP ES clones were left untreated or treated with adriamycin (ADR) at 0.5 μg/ml for 24 h, and protein extracts were prepared.', select the correct biomedical concept corresponding to 'adriamycin'. Answer using one of the provided options. | <Options>: A: methyl (alphae)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]-alpha-(methoxymethylene)benzeneacetate (aka flufenoxystrobin)
B: 17-hydroxylupanine (aka 17-hydroxylupanine(1+))
C: c7h5f3 (aka (trifluoromethyl)benzene)
D: n-methyl-3-phenothiazinylacetic acid (aka metiazinic acid)
E: [h][c@@]12cc[c@@]3([h])[c@]4([h])cc[c@]([h])(c(=o)nc5cc(ccc5c(f)(f)f)c(f)(f)f)[c@@]4(c)cc[c@]3([h])[c@@]1(c)c=cc(=o)n2 (aka dutasteride)
F: beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcp-yl group (beta-d-mannopyranosyl-(1->3)-beta-d-mannopyranosyl-(1->3)-6-deoxy-alpha-l-mannopyranosyl-(1->3)-beta-d-glucopyranosyl) (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcp-yl group)
G: procure (aka triflumizole)
H: beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcpo[ch2]3nh2 (c[c@@h]1o[c@@h](o[c@h]2[c@h](o)[c@@h](co)o[c@@h](occcn)[c@@h]2o)[c@h](o)[c@h](o[c@@h]2o[c@h](co)[c@@h](o)[c@h](o[c@@h]3o[c@h](co)[c@@h](o)[c@h](o)[c@@h]3o)[c@@h]2o)[c@h]1o) (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcpo[ch2]3nh2)
I: c[c@@h](o[c@h]1occn(cc2n[nh]c(=o)[nh]2)[c@h]1c1ccc(f)cc1)c1cc(cc(c1)c(f)(f)f)c(f)(f)f (aka aprepitant)
J: erythromycin c cation (aka erythromycin c(1+))
K: None of the above. | K |
<Instruct>: Given the context 'In the representative western (right), cells from two independent p53+/GFP ES clones were left untreated or treated with adriamycin (ADR) at 0.5 μg/ml for 24 h, and protein extracts were prepared.', select the correct biomedical concept corresponding to 'adr'. Answer using one of the provided options. | <Options>: A: 5,7-dihydroxy-8-(3-methylbut-2-enyl)-6-(3-methylbutanoyl)-4-propyl-2h-chromen-2-one (5,7-dihydroxy-8-(3-methyl-2-butenyl)-6-(3-methyl-1-oxobutyl)-4-propyl-2h-benzopyran-2-one) (aka 5,7-dihydroxy-8-(3-methylbut-2-enyl)-6-(3-methylbutanoyl)-4-propyl-2h-chromen-2-one)
B: cf3ph (aka (trifluoromethyl)benzene)
C: ec 3.6.3.14 (h(+)-transporting two-sector atpase) inhibitor (h(+)-transporting two-sector atpase (ec 3.6.3.14) inhibitors) (aka ec 3.6.3.14 (h(+)-transporting two-sector atpase) inhibitor)
D: c27h44o7 (aka pterosterone)
E: atp phosphohydrolase (ca(2+)-transporting) inhibitors (aka ec 3.6.3.8 (ca(2+)-transporting atpase) inhibitor)
F: l-cys-l-pro (aka cys-pro)
G: beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcp-yl group (beta-d-mannopyranosyl-(1->3)-beta-d-mannopyranosyl-(1->3)-6-deoxy-alpha-l-mannopyranosyl-(1->3)-beta-d-glucopyranosyl) (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcp-yl group)
H: alkaline phosphohydrolase inhibitors (aka ec 3.1.3.1 (alkaline phosphatase) inhibitor)
I: c27h37n7o5s (aka arg-phe-phe-cys)
J: ec 3.6.3.9 inhibitor (aka ec 3.6.3.9 (na(+)/k(+)-transporting atpase) inhibitor)
K: None of the above. | K |
<Instruct>: Given the context '(B) RMCE with the p53ΔPGFP plasmid. p53RMCE/− MEFs, electroporated with a Cre expression plasmid and the p53ΔPGFP plasmid, were selected with ganciclovir.', select the correct biomedical concept corresponding to 'ganciclovir'. Answer using one of the provided options. | <Options>: A: [h][c@@]12cccc[c@]1(c)[c@@]1([h])cc[c@]3(c)ccc[c@@]3([h])[c@]1([h])cc2 (aka 5beta-androstane)
B: 16-androstene (aka androst-16-ene)
C: n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide (aka finasteride)
D: androstenone (aka 5alpha-androst-16-en-3-one)
E: c22h32o3 (aka 17beta-hydroxy-5alpha-androst-1-en-3-one propionate)
F: 7-hydroxy-3-(4-hydroxyphenyl)chroman-4-one (aka dihydrodaidzein)
G: 5alpha-androst-16-ene ([h][c@]12cccc[c@]1(c)[c@@]1([h])cc[c@]3(c)c=cc[c@@]3([h])[c@]1([h])cc2) (aka 5alpha-androst-16-ene)
H: None of the above. | H |
<Instruct>: Given the context 'PCR with primers d and e (Figure 3B) indicated that 9/22 ganciclovir-resistant clones integrated the ΔP mutation', select the correct biomedical concept corresponding to 'ganciclovir'. Answer using one of the provided options. | <Options>: A: 16-androstene (aka androst-16-ene)
B: c19h28o (aka 5alpha-androst-16-en-3-one)
C: c19h30 (aka 5alpha-androst-16-ene)
D: finasterida (aka finasteride)
E: (+/-)-dihydrodaidzein (aka dihydrodaidzein)
F: 5beta-androstane ([h][c@@]12cccc[c@]1(c)[c@@]1([h])cc[c@]3(c)ccc[c@@]3([h])[c@]1([h])cc2) (aka 5beta-androstane)
G: c22h32o3 (aka 17beta-hydroxy-5alpha-androst-1-en-3-one propionate)
H: None of the above. | H |
<Instruct>: Given the context 'Western analysis of positive clones (bottom row) showed that p53ΔPGFP accumulated after ADR, but at lower levels than p53WT.', select the correct biomedical concept corresponding to 'adr'. Answer using one of the provided options. | <Options>: A: ec 3.6.3.14 (h(+)-transporting two-sector atpase) inhibitor (h(+)-transporting two-sector atpase (ec 3.6.3.14) inhibitors) (aka ec 3.6.3.14 (h(+)-transporting two-sector atpase) inhibitor)
B: beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcp-yl group (beta-d-mannopyranosyl-(1->3)-beta-d-mannopyranosyl-(1->3)-6-deoxy-alpha-l-mannopyranosyl-(1->3)-beta-d-glucopyranosyl) (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcp-yl group)
C: ec 3.6.3.9 inhibitor (aka ec 3.6.3.9 (na(+)/k(+)-transporting atpase) inhibitor)
D: atp phosphohydrolase (ca(2+)-transporting) inhibitors (aka ec 3.6.3.8 (ca(2+)-transporting atpase) inhibitor)
E: c27h37n7o5s (aka arg-phe-phe-cys)
F: c5h10o5 (aka beta-d-arabinopyranose)
G: erythromycin c (aka erythromycin c(1+))
H: c27h44o7 (aka pterosterone)
I: c7h5f3 (aka (trifluoromethyl)benzene)
J: beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcpo[ch2]3nh2 (c[c@@h]1o[c@@h](o[c@h]2[c@h](o)[c@@h](co)o[c@@h](occcn)[c@@h]2o)[c@h](o)[c@h](o[c@@h]2o[c@h](co)[c@@h](o)[c@h](o[c@@h]3o[c@h](co)[c@@h](o)[c@h](o)[c@@h]3o)[c@@h]2o)[c@h]1o) (aka beta-d-manp-(1->3)-beta-d-manp-(1->3)-alpha-l-rhap-(1->3)-beta-d-glcpo[ch2]3nh2)
K: None of the above. | K |
<Instruct>: Given the context 'Albino C57BL/6J mice homozygous for a tyrosinase mutation (Tyrc-2J) have higher IOPs than their pigmented counterparts.
', select the correct biomedical concept corresponding to 'pigmented'. Answer using one of the provided options. | <Options>: A: non-polar solvent (non-polar solvents) (aka non-polar solvent)
B: inhibitor of phosphoric monoester hydrolase (ec 3.1.3.*) (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
C: ppt-phosphatase inhibitors (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
D: interleukin-1beta converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
E: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
F: c1a heparanase inhibitors (aka ec 3.2.1.166 (heparanase) inhibitor)
G: 3-methylfumaryl-coenzyme a (aka 3-methylfumaryl-coa)
H: axin stabilizers (aka axin stabilizer)
I: None of the above. | I |
<Instruct>: Given the context 'For example, the iridocorneal angle and aqueous humor drainage structures are open to the anterior chamber and have normal morphology in both BALB/cJ and CBA/CaJ mice (Figure 2).', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
B: oxides of tin (aka tin oxide)
C: l-gamma-glutamyl-l-cysteinylglycine amide (aka glutathione amide)
D: (2s,2's)-5,5'-[disulfanediylbis({(2r)-3-[(2-amino-2-oxoethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid) (aka glutathione amide disulfide)
E: aa-glutathion (aka acetaminophen glutathione conjugate)
F: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
G: n,n-diethyl-1-(10h-phenothiazin-10-yl)propan-2-amine (aka profenamine)
H: None of the above. | H |
<Instruct>: Given the context 'The iridocorneal angle that contains the aqueous humor drainage structures (Schlemm's canal (SC) and trabecular meshwork (TM) had a normal morphology in strains CBA/CaJ (A, high IOP), BALB/cJ (B, low IOP) and all other strains.', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: c20h34n8o10s2 (aka glutathione amide disulfide)
B: acetaminophen glutathion (aka acetaminophen glutathione conjugate)
C: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
D: gash (aka glutathione amide) (aka glutathione amide)
E: 5-methyluridine 5'-phosphate residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
F: oxides of tin (aka tin oxide)
G: 2-diethylamino-1-propyl-n-dibenzoparathiazine (aka profenamine)
H: None of the above. | H |
<Instruct>: Given the context 'Pigment filled macrophages that resemble human clump cells were often located in the angle of CBA/CaJ mice but were never sufficient to block drainage.', select the correct biomedical concept corresponding to 'pigment'. Answer using one of the provided options. | <Options>: A: ppt-phosphatase inhibitors (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
B: interleukin 1beta-converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
C: 4'-hydroxy-3'-methoxyacetophenone (aka apocynin)
D: 3-methylfumaryl-coenzyme a (aka 3-methylfumaryl-coa)
E: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
F: milli-calpain inhibitors (aka ec 3.4.22.53 (calpain-2) inhibitor)
G: c12h15n5o6p (aka n(6),n(6)-dimethyladenosine 5'-monophosphate(1-) residue)
H: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
I: 2-methyladenosine 5'-monophosphate(1-) residue (2-methyladenosine 5'-phosphate residue) (aka 2-methyladenosine 5'-monophosphate(1-) residue)
J: 2'-o-methylcytidine 5'-monophosphate(1-) residue (2'-o-methylcytidine 5'-phosphate residue) (aka 2'-o-methylcytidine 5'-monophosphate(1-) residue)
K: None of the above. | K |
<Instruct>: Given the context 'Aqueous humor passes through this recess before entering the drainage structures.', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: 5-methyluridine 5'-phosphate residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
B: gash disulfide (aka glutathione amide disulfide)
C: 10-[2-(diethylamino)-2-methylethyl]phenothiazine (aka profenamine)
D: l-gamma-glutamyl-l-cysteinylglycine amide (aka glutathione amide)
E: oxides of tin (aka tin oxide)
F: aa-gsh (aka acetaminophen glutathione conjugate)
G: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
H: None of the above. | H |
<Instruct>: Given the context 'Anesthesia protocol avoids IOP alteration and allows detection of diurnal differences
All IOPs were assessed using an anesthetic regime of 99 mg/kg ketamine and 9 mg/kg xylazine (defined as 1X).', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
B: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
C: c4h7n3s (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
D: fm4-64 (aka fm 4-64 dye)
E: c5h8n4se (aka 4-amino-1-methylimidazole-5-carboselenoamide)
F: ccccccccc1c(cc)nc2ncnn2c1n (aka ametoctradin)
G: platensimycin a6 methyl ester ([h][c@]12c[c@]3([h])o[c@@]1(c)c[c@@]1(c2)[c@h](o)cc(=o)[c@@](c)(ccc(=o)nc2c(o)ccc(c(=o)oc)c2o)[c@]31[h]) (aka platensimycin a6 methyl ester)
H: [h][c@@]12cc[c@]3(c[c@]1(o)co)c=cc(=o)[c@@](c)(ccc(=o)nc1c(o)ccc(c(=o)oc)c1o)[c@]3([h])c2 (aka platencin a11 methyl ester)
I: None of the above. | I |
<Instruct>: Given the context 'Initial experiments suggested that an almost identical dose (100 mg/kg ketamine and 9 mg/kg xylazine) of anesthesia had no effect on IOP during the experimental period with IOP being measured as soon as possible after the mouse was unconscious, typically minutes.', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: platensimycin a6 methyl ester ([h][c@]12c[c@]3([h])o[c@@]1(c)c[c@@]1(c2)[c@h](o)cc(=o)[c@@](c)(ccc(=o)nc2c(o)ccc(c(=o)oc)c2o)[c@]31[h]) (aka platensimycin a6 methyl ester)
B: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
C: [h][c@@]12cc[c@]3(c[c@]1(o)co)c=cc(=o)[c@@](c)(ccc(=o)nc1c(o)ccc(c(=o)oc)c1o)[c@]3([h])c2 (aka platencin a11 methyl ester)
D: 4-amino-1-methyl-1h-imidazole-5-carboselenoamide (aka 4-amino-1-methylimidazole-5-carboselenoamide)
E: ccccccccc1c(cc)nc2ncnn2c1n (aka ametoctradin)
F: c34h53br2n3 (aka fm 4-64 dye)
G: 5-ethyl-1,3,4-thiadiazol-2-amine (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
H: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
I: None of the above. | I |
<Instruct>: Given the context 'A Mean IOP ± SD is shown for C57BL/6J mice at 5 and 25 minutes after administration of various doses of anesthetic.', select the correct biomedical concept corresponding to 'anesthetic'. Answer using one of the provided options. | <Options>: A: chymase inhibitor (aka ec 3.4.21.39 (chymase) inhibitor)
B: sperm receptor hydrolase inhibitor (aka ec 3.4.21.4 (trypsin) inhibitor)
C: beta-esterase inhibitors (aka ec 3.1.1.1 (carboxylesterase) inhibitor)
D: serine proteinase inhibitors (aka serine proteinase inhibitor)
E: None of the above. | E |
<Instruct>: Given the context 'The 1X dose consisted of 99 mg/kg ketamine and 9 mg/kg xylazine.', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
B: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
C: c34h53br2n3 (aka fm 4-64 dye)
D: c25h31no8 (aka platencin a11 methyl ester)
E: 5-ethyl-1,3,4-thiadiazol-2-amine (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
F: c25h31no8 (aka platensimycin a6 methyl ester)
G: bas-650f (aka ametoctradin)
H: cn1cnc(n)c1c(n)=[se] (aka 4-amino-1-methylimidazole-5-carboselenoamide)
I: None of the above. | I |
<Instruct>: Given the context 'Tyr
To determine if albinism alters IOP, we analyzed B6 mice that were either pigmented or albino.', select the correct biomedical concept corresponding to 'pigmented'. Answer using one of the provided options. | <Options>: A: phosphoric monoester hydrolase (ec 3.1.3.*) inhibitor (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
B: non-polar solvent (non-polar solvents) (aka non-polar solvent)
C: mesaconyl-c4-coa (aka 3-methylfumaryl-coa)
D: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
E: interleukin-1beta converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
F: ppt-phosphatase inhibitor (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
G: axin stabilizer (axin stabilizers) (aka axin stabilizer)
H: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
I: None of the above. | I |
<Instruct>: Given the context 'The albino mice were homozygous and coisogenic for a mutant allele of tyrosinase (Tyrc-2J) that arose on the otherwise pigmented B6 background.', select the correct biomedical concept corresponding to 'pigmented'. Answer using one of the provided options. | <Options>: A: non-polar solvent (non-polar solvents) (aka non-polar solvent)
B: deaminase inhibitor (aka ec 3.5.1.4 (amidase) inhibitor)
C: c1a heparanase inhibitors (aka ec 3.2.1.166 (heparanase) inhibitor)
D: interleukin-1beta converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
E: axin stabilizers (aka axin stabilizer)
F: tyrosylprotein phosphatase inhibitor (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
G: phosphoric monoester hydrolase (ec 3.1.3.*) inhibitor (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
H: 3-methylfumaryl-coenzyme a (aka 3-methylfumaryl-coa)
I: None of the above. | I |
<Instruct>: Given the context 'In 2 month old mice, homozygosity for Tyrc-2J resulted in increased IOP (14.2 ± 0.4 mmHg) compared to wild type, pigmented mice (12.4 ± 0.3 mmHg, P < 0.0001).', select the correct biomedical concept corresponding to 'pigmented'. Answer using one of the provided options. | <Options>: A: axin stabilizers (aka axin stabilizer)
B: non-polar solvent (non-polar solvents) (aka non-polar solvent)
C: mesaconyl-c4-coa (aka 3-methylfumaryl-coa)
D: c1a heparanase inhibitors (aka ec 3.2.1.166 (heparanase) inhibitor)
E: inhibitor of phosphoric monoester hydrolase (ec 3.1.3.*) (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
F: phosphotyrosine phosphatase inhibitor (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
G: interleukin-1beta converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
H: deaminase inhibitor (aka ec 3.5.1.4 (amidase) inhibitor)
I: None of the above. | I |
<Instruct>: Given the context 'In contrast to pigmented B6 mice (Figure 6), the IOPs of the albino B6 mice were not increased at measurement during the dark compared to light period of the day (P = 0.6, Figure 10B).
', select the correct biomedical concept corresponding to 'pigmented'. Answer using one of the provided options. | <Options>: A: phosphoric monoester hydrolase (ec 3.1.3.*) inhibitor (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
B: non-polar solvent (non-polar solvents) (aka non-polar solvent)
C: axin stabilizer (axin stabilizers) (aka axin stabilizer)
D: interleukin 1beta-converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
E: 3-methylfumaryl-coenzyme a (aka 3-methylfumaryl-coa)
F: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
G: ptp-phosphatase inhibitors (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
H: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
I: None of the above. | I |
<Instruct>: Given the context 'These are important approaches as they may allow the association of genes with IOP and glaucoma whose currently known functions do not suggest that they affect aqueous humor dynamics or do not immediately identify them as likely glaucoma candidates.
', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: gash disulfide (aka glutathione amide disulfide)
B: acetaminophen glutathion (aka acetaminophen glutathione conjugate)
C: n[c@@h](ccc(=o)n[c@@h](cs)c(=o)ncc(n)=o)c(o)=o (aka glutathione amide)
D: 2-diethylamino-1-propyl-n-dibenzoparathiazine (aka profenamine)
E: oxides of tin (aka tin oxide)
F: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
G: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
H: None of the above. | H |
<Instruct>: Given the context 'No effect of anesthetic protocol on IOP during a 12 minute measurement window
Many anesthetic agents including xylazine lower IOP.', select the correct biomedical concept corresponding to 'anesthetic agents'. Answer using one of the provided options. | <Options>: A: methylbutyrase inhibitor (aka ec 3.1.1.1 (carboxylesterase) inhibitor)
B: serine proteinase inhibitor (serine proteinase inhibitors) (aka serine proteinase inhibitor)
C: chymase inhibitor (aka ec 3.4.21.39 (chymase) inhibitor)
D: trypsin inhibitors (aka ec 3.4.21.4 (trypsin) inhibitor)
E: None of the above. | E |
<Instruct>: Given the context 'Ketamine usually appears to increase IOP', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: bas-650f (aka ametoctradin)
B: c25h31no8 (aka platencin a11 methyl ester)
C: [h][c@]12c[c@]3([h])o[c@@]1(c)c[c@@]1(c2)[c@h](o)cc(=o)[c@@](c)(ccc(=o)nc2c(o)ccc(c(=o)oc)c2o)[c@]31[h] (aka platensimycin a6 methyl ester)
D: c4h7n3s (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
E: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
F: fm4-64 (aka fm 4-64 dye)
G: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
H: 4-amino-1-methyl-1h-imidazole-5-carboselenoamide (aka 4-amino-1-methylimidazole-5-carboselenoamide)
I: None of the above. | I |
<Instruct>: Given the context '[31-33], but there are reports of ketamine having no effect on IOP or even reducing IOP [31,34].', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
B: bas-650f (aka ametoctradin)
C: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
D: [br-].[br-].ccccn(cccc)c1ccc(c=cc=cc=cc2cc[n+](ccc[n+](cc)(cc)cc)cc2)cc1 (aka fm 4-64 dye)
E: [h][c@]12c[c@]3([h])o[c@@]1(c)c[c@@]1(c2)[c@h](o)cc(=o)[c@@](c)(ccc(=o)nc2c(o)ccc(c(=o)oc)c2o)[c@]31[h] (aka platensimycin a6 methyl ester)
F: 5-ethyl-1,3,4-thiadiazol-2-amine (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
G: [h][c@@]12cc[c@]3(c[c@]1(o)co)c=cc(=o)[c@@](c)(ccc(=o)nc1c(o)ccc(c(=o)oc)c1o)[c@]3([h])c2 (aka platencin a11 methyl ester)
H: 4-amino-1-methylimidazole-5-carboselenoamide (4-amino-1-methyl-1h-imidazole-5-carboselenoamide) (aka 4-amino-1-methylimidazole-5-carboselenoamide)
I: None of the above. | I |
<Instruct>: Given the context 'The relationship between the IOPs we measure and those in conscious mice depends upon the effect of our anesthetic protocol (intraperitoneal injection of 99 mg/kg ketamine and 9 mg/kg xylazine).', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: cn1cnc(n)c1c(n)=[se] (aka 4-amino-1-methylimidazole-5-carboselenoamide)
B: fm 4-64 dye (4-{6-[4-(dibutylamino)phenyl]hexa-1,3,5-trien-1-yl}-1-[3-(triethylammonio)propyl]pyridinium dibromide) (aka fm 4-64 dye)
C: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
D: [h][c@]12c[c@]3([h])o[c@@]1(c)c[c@@]1(c2)[c@h](o)cc(=o)[c@@](c)(ccc(=o)nc2c(o)ccc(c(=o)oc)c2o)[c@]31[h] (aka platensimycin a6 methyl ester)
E: 5-ethyl-1,3,4-thiadiazol-2-amine (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
F: c25h31no8 (aka platencin a11 methyl ester)
G: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
H: ccccccccc1c(cc)nc2ncnn2c1n (aka ametoctradin)
I: None of the above. | I |
<Instruct>: Given the context 'Similarities and differences to rat studies
Our results agree with the time course of cardiovascular depression caused by intraperitoneal administration of ketamine and xylazine in rats.', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: fm4-64 (aka fm 4-64 dye)
B: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
C: [h][c@@]12cc[c@]3(c[c@]1(o)co)c=cc(=o)[c@@](c)(ccc(=o)nc1c(o)ccc(c(=o)oc)c1o)[c@]3([h])c2 (aka platencin a11 methyl ester)
D: 4-amino-1-methyl-1h-imidazole-5-carboselenoamide (aka 4-amino-1-methylimidazole-5-carboselenoamide)
E: 5-ethyl-1,3,4-thiadiazol-2-amine (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
F: platensimycin a6 methyl ester ([h][c@]12c[c@]3([h])o[c@@]1(c)c[c@@]1(c2)[c@h](o)cc(=o)[c@@](c)(ccc(=o)nc2c(o)ccc(c(=o)oc)c2o)[c@]31[h]) (aka platensimycin a6 methyl ester)
G: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
H: ccccccccc1c(cc)nc2ncnn2c1n (aka ametoctradin)
I: None of the above. | I |
<Instruct>: Given the context 'In contrast, intraperitoneally administered ketamine (100 mg/kg) was shown to rapidly decrease IOP in a different rat study [36].', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
B: bas-650f (aka ametoctradin)
C: fm 4-64 dye (4-{6-[4-(dibutylamino)phenyl]hexa-1,3,5-trien-1-yl}-1-[3-(triethylammonio)propyl]pyridinium dibromide) (aka fm 4-64 dye)
D: c25h31no8 (aka platencin a11 methyl ester)
E: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
F: [h][c@]12c[c@]3([h])o[c@@]1(c)c[c@@]1(c2)[c@h](o)cc(=o)[c@@](c)(ccc(=o)nc2c(o)ccc(c(=o)oc)c2o)[c@]31[h] (aka platensimycin a6 methyl ester)
G: 2-amino-5-ethyl-1,3,4-thiadiazole (5-ethyl-1,3,4-thiadiazol-2-amine) (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
H: 4-amino-1-methylimidazole-5-carboselenoamide (4-amino-1-methyl-1h-imidazole-5-carboselenoamide) (aka 4-amino-1-methylimidazole-5-carboselenoamide)
I: None of the above. | I |
<Instruct>: Given the context 'Essentially the same dose of ketamine and route of administration was used in both the rat and mouse IOP studies.', select the correct biomedical concept corresponding to 'ketamine'. Answer using one of the provided options. | <Options>: A: fm4-64 (aka fm 4-64 dye)
B: c4h7n3s (aka 2-amino-5-ethyl-1,3,4-thiadiazole)
C: lissamine flavine ff free acid (6-amino-2-(4-methylphenyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinoline-5-sulfonic acid) (aka lissamine flavine ff free acid)
D: c25h31no8 (aka platensimycin a6 methyl ester)
E: 4-amino-1-methylimidazole-5-carboselenoamide (4-amino-1-methyl-1h-imidazole-5-carboselenoamide) (aka 4-amino-1-methylimidazole-5-carboselenoamide)
F: [h][c@@]12cc[c@]3(c[c@]1(o)co)c=cc(=o)[c@@](c)(ccc(=o)nc1c(o)ccc(c(=o)oc)c1o)[c@]3([h])c2 (aka platencin a11 methyl ester)
G: ccccccccc1c(cc)nc2ncnn2c1n (aka ametoctradin)
H: czc8004 (n(2)-[4-(aminomethyl)phenyl]-5-fluoro-n(4)-phenylpyrimidine-2,4-diamine) (aka czc8004)
I: None of the above. | I |
<Instruct>: Given the context 'Cage cleanliness, changing frequency and housing density can alter drug metabolism and the effect of anesthesia in rats [38,39].', select the correct biomedical concept corresponding to 'drug'. Answer using one of the provided options. | <Options>: A: deoxyadenosine deaminase inhibitors (aka ec 3.5.4.4 (adenosine deaminase) inhibitor)
B: (sp-4-1)-diamminedichloroplatinum (aka transplatin)
C: [pa] (aka protactinium atom) (aka protactinium atom)
D: cholinesterase (ec 3.1.1.8) inhibitor (aka ec 3.1.1.8 (cholinesterase) inhibitor)
E: ali-esterase inhibitor (aka ec 3.1.1.1 (carboxylesterase) inhibitor)
F: calpain-1 (ec 3.4.22.52) inhibitor (aka ec 3.4.22.52 (calpain-1) inhibitor)
G: None of the above. | G |
<Instruct>: Given the context 'We use wood shavings for bedding and wood shavings expose the mice to terpenes.', select the correct biomedical concept corresponding to 'terpenes'. Answer using one of the provided options. | <Options>: A: 11beta-hydroxy steroid (an 11beta-hydroxysteroid) (aka 11beta-hydroxy steroid)
B: 3,4,3',4',5'-pentachlorobiphenyl (aka 3,3',4,4',5-pentachlorobiphenyl)
C: [h][c@@]12ccc3=cc(=o)cc[c@]3(c)[c@@]1([h])[c@@h](o)c[c@]1(c)c(=o)cc[c@@]21[h] (aka 11beta-hydroxyandrost-4-ene-3,17-dione)
D: c27h50o11 (aka glas#26)
E: (+)-bifonazole (aka (s)-bifonazole)
F: rac-bifonazole (aka bifonazole)
G: (3r,14r)-3,14-dihydroxypentadecanoic acid ((r,r)-3,14-dihydroxypentadecanoic acid) (aka (3r,14r)-3,14-dihydroxypentadecanoic acid)
H: rel-(11alpha,22e)-9,11-dihydroxyergosta-4,6,8(14),22-tetraen-3-one (aka 9alpha,11alpha-dihydroxyergosta-4,6,8(14),22-tetraen-3-one)
I: 4-chlorodiphenyl (aka 4-chlorobiphenyl)
J: None of the above. | J |
<Instruct>: Given the context 'Terpene administration or environmental exposure to terpenes in wood shavings alters drug resistance and decreases the effect of anesthetic agents in both rats and mice [40-45].
', select the correct biomedical concept corresponding to 'terpene'. Answer using one of the provided options. | <Options>: A: c27h50o11 (aka glas#26)
B: 4-chlorodiphenyl (aka 4-chlorobiphenyl)
C: 3,4,3',4',5'-pentachlorobiphenyl (aka 3,3',4,4',5-pentachlorobiphenyl)
D: (+)-bifonazole (aka (s)-bifonazole)
E: 11beta-hydroxy steroid (an 11beta-hydroxysteroid) (aka 11beta-hydroxy steroid)
F: [h][c@@]12ccc3=cc(=o)cc[c@]3(c)[c@@]1([h])[c@@h](o)c[c@]1(c)c(=o)cc[c@@]21[h] (aka 11beta-hydroxyandrost-4-ene-3,17-dione)
G: rel-(11alpha,22e)-9,11-dihydroxyergosta-4,6,8(14),22-tetraen-3-one (aka 9alpha,11alpha-dihydroxyergosta-4,6,8(14),22-tetraen-3-one)
H: (3r,14r)-3,14-dihydroxypentadecanoic acid ((r,r)-3,14-dihydroxypentadecanoic acid) (aka (3r,14r)-3,14-dihydroxypentadecanoic acid)
I: (+-)-bifonazole (aka bifonazole)
J: None of the above. | J |
<Instruct>: Given the context 'Terpene administration or environmental exposure to terpenes in wood shavings alters drug resistance and decreases the effect of anesthetic agents in both rats and mice [40-45].
', select the correct biomedical concept corresponding to 'terpenes'. Answer using one of the provided options. | <Options>: A: c27h50o11 (aka glas#26)
B: (3r,14r)-3,14-dihydroxypentadecanoic acid ((r,r)-3,14-dihydroxypentadecanoic acid) (aka (3r,14r)-3,14-dihydroxypentadecanoic acid)
C: p-chlorobiphenyl (aka 4-chlorobiphenyl)
D: rel-(11alpha,22e)-9,11-dihydroxyergosta-4,6,8(14),22-tetraen-3-one (aka 9alpha,11alpha-dihydroxyergosta-4,6,8(14),22-tetraen-3-one)
E: 11beta-hydroxy steroid (an 11beta-hydroxysteroid) (aka 11beta-hydroxy steroid)
F: (+)-bifonazole (aka (s)-bifonazole)
G: androst-4-ene-3,17-dione-11beta-ol (aka 11beta-hydroxyandrost-4-ene-3,17-dione)
H: 1-((4-biphenylyl)phenylmethyl)-1h-imidazole (aka bifonazole)
I: 3,4,3',4',5'-pentachlorobiphenyl (aka 3,3',4,4',5-pentachlorobiphenyl)
J: None of the above. | J |
<Instruct>: Given the context 'Terpene administration or environmental exposure to terpenes in wood shavings alters drug resistance and decreases the effect of anesthetic agents in both rats and mice [40-45].
', select the correct biomedical concept corresponding to 'anesthetic agents'. Answer using one of the provided options. | <Options>: A: chymase inhibitor (aka ec 3.4.21.39 (chymase) inhibitor)
B: sperm receptor hydrolase inhibitors (aka ec 3.4.21.4 (trypsin) inhibitor)
C: monobutyrase inhibitors (aka ec 3.1.1.1 (carboxylesterase) inhibitor)
D: serine proteinase inhibitors (aka serine proteinase inhibitor)
E: None of the above. | E |
<Instruct>: Given the context 'Terpene administration or environmental exposure to terpenes in wood shavings alters drug resistance and decreases the effect of anesthetic agents in both rats and mice [40-45].
', select the correct biomedical concept corresponding to 'drug'. Answer using one of the provided options. | <Options>: A: deoxyadenosine deaminase inhibitors (aka ec 3.5.4.4 (adenosine deaminase) inhibitor)
B: [pa] (aka protactinium atom) (aka protactinium atom)
C: trans-platinumdiammine dichloride (aka transplatin)
D: non-specific cholinesterase inhibitor (aka ec 3.1.1.8 (cholinesterase) inhibitor)
E: carboxylesterase inhibitor (aka ec 3.1.1.1 (carboxylesterase) inhibitor)
F: calpain-1 (ec 3.4.22.52) inhibitor (aka ec 3.4.22.52 (calpain-1) inhibitor)
G: None of the above. | G |
<Instruct>: Given the context 'The molecular mechanisms underlying the diurnal rhythm are not defined but increased aqueous humor production or flow occurs during the period of increased IOP in both rabbits and humans', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
B: 2-diethylamino-1-propyl-n-dibenzoparathiazine (aka profenamine)
C: acetaminophen glutathion (aka acetaminophen glutathione conjugate)
D: (2s,2's)-5,5'-[disulfanediylbis({(2r)-3-[(2-amino-2-oxoethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid) (aka glutathione amide disulfide)
E: glutathione amide (n[c@@h](ccc(=o)n[c@@h](cs)c(=o)ncc(n)=o)c(o)=o) (aka glutathione amide)
F: oxides of tin (aka tin oxide)
G: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
H: None of the above. | H |
<Instruct>: Given the context 'Small changes in the resistance to aqueous humor drainage may also contribute to diurnal differences in IOP', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: glutathione amide (n[c@@h](ccc(=o)n[c@@h](cs)c(=o)ncc(n)=o)c(o)=o) (aka glutathione amide)
B: oxides of tin (aka tin oxide)
C: (2s,2's)-5,5'-[disulfanediylbis({(2r)-3-[(2-amino-2-oxoethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid) (aka glutathione amide disulfide)
D: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
E: n,n-diethyl-1-(10h-phenothiazin-10-yl)propan-2-amine (aka profenamine)
F: aa-glutathion (aka acetaminophen glutathione conjugate)
G: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
H: None of the above. | H |
<Instruct>: Given the context 'Car2 deficiency does not alter IOP
Bicarbonate formation is important for aqueous humor secretion from the ciliary processes and carbonic anhydrase (CA) facilitates this secretion.', select the correct biomedical concept corresponding to 'bicarbonate'. Answer using one of the provided options. | <Options>: A: 7-hydroxy-1-(4-hydroxybenzyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolinium (aka (rs)-coclaurinium)
B: cc(c)cccccccccc[c@@h](o)[c@@h](o)[c@h](co[c@@h]1o[c@h](co)[c@@h](o)[c@h](o)[c@h]1o)nc([*])=o (aka n-hexacosadienoyl-1-o-beta-d-glucosyl-4-hydroxy-15-methylhexadecasphinganine)
C: (1r,2s,3s,4r,6s)-4,6-diammmonio-3-(3-ammonio-3-deoxy-alpha-d-glucopyranosyloxy)-2-hydroxycyclohexyl 2,6-diammmonio-2,6-dideoxy-alpha-d-glucopyranoside (aka kanamycin b(5+))
D: n(8)-acetylspermidinium(2+) (n-(4-acetamidobutyl)propane-1,3-diaminium) (aka n(8)-acetylspermidinium(2+))
E: 1d-myo-inositol 4,5-bisphosphate ((1r,2r,3s,4r,5s,6s)-3,4,5,6-tetrahydroxycyclohexane-1,2-diyl bis[dihydrogen (phosphate)]) (aka 1d-myo-inositol 4,5-bisphosphate)
F: alizarin red s (aka alizarin red)
G: lanthanum(3+) (lanthanum(iii) cation) (aka lanthanum(3+))
H: sodium nitrite (nitrite de sodium) (aka sodium nitrite)
I: ammonium hexachloroiridate(iv) (aka ammonium hexachloroiridate)
J: None of the above. | J |
<Instruct>: Given the context 'Car2 deficiency does not alter IOP
Bicarbonate formation is important for aqueous humor secretion from the ciliary processes and carbonic anhydrase (CA) facilitates this secretion.', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: n,n-diethyl-1-(10h-phenothiazin-10-yl)propan-2-amine (aka profenamine)
B: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
C: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
D: aa-gsh (aka acetaminophen glutathione conjugate)
E: oxides of tin (aka tin oxide)
F: c20h34n8o10s2 (aka glutathione amide disulfide)
G: n[c@@h](ccc(=o)n[c@@h](cs)c(=o)ncc(n)=o)c(o)=o (aka glutathione amide)
H: None of the above. | H |
<Instruct>: Given the context 'CAIV activity was recently demonstrated in the ciliary processes [73] and so our data may support a more substantial role for CAIV compared to CAII in aqueous humor secretion.', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: oxides of tin (aka tin oxide)
B: l-gamma-glutamyl-l-cysteinylglycine amide (aka glutathione amide)
C: 3-(glutathion-s-yl)acetaminophen (aka acetaminophen glutathione conjugate)
D: glutathione amide disulfide ((2s,2's)-5,5'-[disulfanediylbis({(2r)-3-[(2-amino-2-oxoethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid)) (aka glutathione amide disulfide)
E: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
F: 10-[2-(diethylamino)-2-methylethyl]phenothiazine (aka profenamine)
G: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
H: None of the above. | H |
<Instruct>: Given the context 'It also is possible that CAII substantially contributes to aqueous humor secretion but that functional mouse CAIV is sufficient to prevent an effect of CAII deficiency on IOP in Car2 mutant mice.', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: n[c@@h](ccc(=o)n[c@@h](cssc[c@h](nc(=o)cc[c@h](n)c(o)=o)c(=o)ncc(n)=o)c(=o)ncc(n)=o)c(o)=o (aka glutathione amide disulfide)
B: n[c@@h](ccc(=o)n[c@@h](cs)c(=o)ncc(n)=o)c(o)=o (aka glutathione amide)
C: 10-[2-(diethylamino)-2-methylethyl]phenothiazine (aka profenamine)
D: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
E: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
F: oxides of tin (aka tin oxide)
G: aa-glutathion (aka acetaminophen glutathione conjugate)
H: None of the above. | H |
<Instruct>: Given the context 'In support of a role for both enzymes, a greater than 90% inhibition of CA is required for significant reduction of aqueous secretion [71,72].
', select the correct biomedical concept corresponding to 'aqueous'. Answer using one of the provided options. | <Options>: A: oxides of tin (aka tin oxide)
B: 2-diethylamino-1-propyl-n-dibenzoparathiazine (aka profenamine)
C: 3-(glutathion-s-yl)acetaminophen (aka acetaminophen glutathione conjugate)
D: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
E: n[c@@h](ccc(=o)n[c@@h](cs)c(=o)ncc(n)=o)c(o)=o (aka glutathione amide)
F: tmp(1-) residue (aka 5-methyluridine 5'-monophosphate(1-) residue)
G: c20h34n8o10s2 (aka glutathione amide disulfide)
H: None of the above. | H |
<Instruct>: Given the context 'Tyrosinase deficiency results in increased IOP
Tyrosinase is the first enzyme of the pigment production pathway.', select the correct biomedical concept corresponding to 'pigment'. Answer using one of the provided options. | <Options>: A: mesaconyl-c4-coa (aka 3-methylfumaryl-coa)
B: calpain-2 (ec 3.4.22.53) inhibitor (aka ec 3.4.22.53 (calpain-2) inhibitor)
C: 2-methyladenosine 5'-monophosphate(1-) residue (2-methyladenosine 5'-phosphate residue) (aka 2-methyladenosine 5'-monophosphate(1-) residue)
D: c12h15n5o6p (aka n(6),n(6)-dimethyladenosine 5'-monophosphate(1-) residue)
E: interleukin 1beta-converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
F: 4'-hydroxy-3'-methoxyacetophenone (aka apocynin)
G: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
H: smase inhibitors (aka ec 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor)
I: 2'-o-methylcytidine 5'-monophosphate(1-) residue (2'-o-methylcytidine 5'-phosphate residue) (aka 2'-o-methylcytidine 5'-monophosphate(1-) residue)
J: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
K: None of the above. | K |
<Instruct>: Given the context 'Here, we show increased IOP in mice lacking tyrosinase activity compared to otherwise genetically identical pigmented B6 mice.', select the correct biomedical concept corresponding to 'pigmented'. Answer using one of the provided options. | <Options>: A: phosphoric monoester hydrolase (ec 3.1.3.*) inhibitor (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
B: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
C: mesaconyl-c4-coa (aka 3-methylfumaryl-coa)
D: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
E: ppt-phosphatase inhibitors (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
F: axin stabilizers (aka axin stabilizer)
G: interleukin-1beta converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
H: non-polar solvent (non-polar solvents) (aka non-polar solvent)
I: None of the above. | I |
<Instruct>: Given the context 'Additionally, IOP differences between the light and dark period of the day were detected in the pigmented but not the albino B6 mice.', select the correct biomedical concept corresponding to 'pigmented'. Answer using one of the provided options. | <Options>: A: ppt-phosphatase inhibitor (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
B: interleukin-1beta converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
C: c1a heparanase inhibitors (aka ec 3.2.1.166 (heparanase) inhibitor)
D: inhibitor of phosphoric monoester hydrolase (ec 3.1.3.*) (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
E: deaminase inhibitor (aka ec 3.5.1.4 (amidase) inhibitor)
F: mesaconyl-c4-coa (aka 3-methylfumaryl-coa)
G: axin stabilizers (aka axin stabilizer)
H: non-polar solvent (non-polar solvents) (aka non-polar solvent)
I: None of the above. | I |
<Instruct>: Given the context 'In agreement with this result, mice with albino eyes that are homozygous for tyrosinase or pink eye dilution mutations have altered diurnal rhythms compared to pigmented mice [75].', select the correct biomedical concept corresponding to 'pigmented'. Answer using one of the provided options. | <Options>: A: axin stabilizer (axin stabilizers) (aka axin stabilizer)
B: hpa1 heparanase inhibitor (aka ec 3.2.1.166 (heparanase) inhibitor)
C: amidase inhibitors (aka ec 3.5.1.4 (amidase) inhibitor)
D: mesaconyl-c4-coa (aka 3-methylfumaryl-coa)
E: non-polar solvent (non-polar solvents) (aka non-polar solvent)
F: interleukin 1beta-converting enzyme inhibitors (aka ec 3.4.22.36 (caspase-1) inhibitor)
G: phosphoric monoester hydrolase (ec 3.1.3.*) inhibitor (aka ec 3.1.3.* (phosphoric monoester hydrolase) inhibitor)
H: ppt-phosphatase inhibitors (aka ec 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor)
I: None of the above. | I |
<Instruct>: Given the context 'For most experiments, the mice were fed NIH31 (6 % fat) chow ad libitum, and their water was acidified to pH 2.8 to 3.2.', select the correct biomedical concept corresponding to 'water'. Answer using one of the provided options. | <Options>: A: oxides of tin (aka tin oxide)
B: glutathione amide disulfide ((2s,2's)-5,5'-[disulfanediylbis({(2r)-3-[(2-amino-2-oxoethyl)amino]-3-oxopropane-1,2-diyl}imino)]bis(2-amino-5-oxopentanoic acid)) (aka glutathione amide disulfide)
C: gash (aka glutathione amide) (aka glutathione amide)
D: tirapazamine (3-amino-1,2,4-benzotriazine 1,4-dioxide) (aka tirapazamine)
E: 6-anilinoquinoline-5,8-dione (aka 6-anilino-5,8-quinolinedione)
F: aa-glutathion (aka acetaminophen glutathione conjugate)
G: hydrogenobyrinic acid a,c-diamide ([h][c@]12n=c(\c(c)=c3/n=c(/c=c4\n=c(\c(c)=c5/n[c@]1(c)[c@@](c)(cc(n)=o)[c@@h]5ccc(o)=o)[c@@](c)(cc(n)=o)[c@@h]4ccc(o)=o)c(c)(c)[c@@h]3ccc(o)=o)[c@](c)(ccc(o)=o)[c@h]2cc(o)=o) (aka hydrogenobyrinic acid a,c-diamide)
H: None of the above. | H |
<Instruct>: Given the context 'For most experiments, the mice were fed NIH31 (6 % fat) chow ad libitum, and their water was acidified to pH 2.8 to 3.2.', select the correct biomedical concept corresponding to 'chow'. Answer using one of the provided options. | <Options>: A: c6h3clo4 (aka cis-2-chloro-4-carboxymethylenebut-2-en-1,4-olide)
B: c20h32o5 (aka 13,14-dihydro-15-oxo-prostaglandin e2)
C: n-methylphenazonium methosulfate (aka 5-methylphenazinium methyl sulfate)
D: cis-3-hexen-1-yl acetate (aka (3z)-hex-3-en-1-yl acetate)
E: mitochondrial complex iv inhibitors (aka ec 1.9.3.1 (cytochrome c oxidase) inhibitor)
F: (diethylamino)ethane (aka triethylamine)
G: n-tosyl salicylaldehyde imines (aka salicylaldehyde n-tosylimines)
H: x-prolyl dipeptidyl aminopeptidase inhibitors (aka ec 3.4.14.5 (dipeptidyl-peptidase iv) inhibitor)
I: salicylaldehyde n-tosylimine (n-[(2-hydroxyphenyl)methylidene]-4-methylbenzenesulfonamide) (aka salicylaldehyde n-tosylimine)
J: axin stabilizers (aka axin stabilizer)
K: None of the above. | K |
<Instruct>: Given the context 'To ensure that we were analyzing the effect of age and not diabetes, the B6 mice in the aging experiment were fed NIH31 (4% fat) chow.', select the correct biomedical concept corresponding to 'chow'. Answer using one of the provided options. | <Options>: A: n-methylphenazonium methosulfate (aka 5-methylphenazinium methyl sulfate)
B: cytochrome c oxidase inhibitors (aka ec 1.9.3.1 (cytochrome c oxidase) inhibitor)
C: (diethylamino)ethane (aka triethylamine)
D: axin stabilizers (aka axin stabilizer)
E: x-prolyl dipeptidyl aminopeptidase inhibitor (aka ec 3.4.14.5 (dipeptidyl-peptidase iv) inhibitor)
F: c6h3clo4 (aka cis-2-chloro-4-carboxymethylenebut-2-en-1,4-olide)
G: n-tosyl salicylaldehyde imines (aka salicylaldehyde n-tosylimines)
H: cis-3-hexen-1-yl acetate (aka (3z)-hex-3-en-1-yl acetate)
I: salicylaldehyde n-tosylimine (n-[(2-hydroxyphenyl)methylidene]-4-methylbenzenesulfonamide) (aka salicylaldehyde n-tosylimine)
J: c20h32o5 (aka 13,14-dihydro-15-oxo-prostaglandin e2)
K: None of the above. | K |
<Instruct>: Given the context 'Each mouse was briefly exposed to the red light when the anesthetic agents were administered.', select the correct biomedical concept corresponding to 'anesthetic agents'. Answer using one of the provided options. | <Options>: A: methylbutyrase inhibitor (aka ec 3.1.1.1 (carboxylesterase) inhibitor)
B: ec 3.4.21.4 inhibitors (aka ec 3.4.21.4 (trypsin) inhibitor)
C: chymase inhibitor (aka ec 3.4.21.39 (chymase) inhibitor)
D: serine proteinase inhibitor (serine proteinase inhibitors) (aka serine proteinase inhibitor)
E: None of the above. | E |
<Instruct>: Given the context 'Histological analysis
Eyes from at least 2 mice of the listed strains were fixed (4% paraformaldehyde or Fekete's acid-alcohol-formalin fixative) processed, paraffin embedded and sectioned as previously reported [15,79], except that the paraformaldehyde was buffered with 0.1 M phosphate buffer.', select the correct biomedical concept corresponding to 'acid'. Answer using one of the provided options. | <Options>: A: ns 398 (aka ns-398)
B: (3s,4s,5r,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol (aka d-mannopyranose)
C: p-nitrophenylphosphate phosphohydrolase inhibitor (aka ec 3.1.3.41 (4-nitrophenylphosphatase) inhibitor)
D: thiosalicylate(1-) (2-sulfanylbenzoate) (aka thiosalicylate(1-))
E: transfer rna-thr (aka trna(thr))
F: c10h12o2 (aka p-cumic acid)
G: c[c@h](c[c@@h](o)c=c(c)c)[c@h]1cc[c@@]2(c)[c@@h]3[c@@h](o)c[c@@h]4[c@]5(c[c@@]35cc[c@]12c)ccc(=o)c4(c)c (aka combretanone d)
H: c6h20o30p8 (aka 1d-myo-inositol bis(diphosphate) tetrakisphosphate)
I: cc(c)(n)cc1ccc(cl)cc1 (aka chlorphentermine)
J: op(o)(=o)o[c@h]1[c@@h](op(o)(o)=o)[c@@h](op(o)(o)=o)[c@h](op(o)(=o)op(o)(o)=o)[c@@h](op(o)(=o)op(o)(o)=o)[c@@h]1op(o)(o)=o (aka 5,6-bis(diphospho)-1d-myo-inositol tetrakisphosphate)
K: None of the above. | K |
<Instruct>: Given the context 'Histological analysis
Eyes from at least 2 mice of the listed strains were fixed (4% paraformaldehyde or Fekete's acid-alcohol-formalin fixative) processed, paraffin embedded and sectioned as previously reported [15,79], except that the paraformaldehyde was buffered with 0.1 M phosphate buffer.', select the correct biomedical concept corresponding to 'alcohol'. Answer using one of the provided options. | <Options>: A: (5z,8z,11z,14z,17z)-19-hydroxyicosapentaenoic acid (aka 19-hepe)
B: methyl {5-[(s)-propylsulfinyl]-1h-benzimidazol-2-yl}carbamate (aka (s)-albendazole s-oxide)
C: deltanit (aka furathiocarb)
D: 3-oxovalproic acid (2-n-propyl-3-oxopentanoic acid) (aka 3-oxovalproic acid)
E: physostigmine ((3as,8ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate) (aka physostigmine)
F: 5-oh-vpa (aka 5-hydroxyvalproic acid)
G: mitomycin (mitomycins) (aka mitomycin)
H: c30h50o (aka obtusifoliol)
I: 5alpha-ergosta-7,22-diene-3beta,5-diol ([h][c@@]1(cc[c@@]2([h])c3=cc[c@@]4(o)c[c@@h](o)cc[c@]4(c)[c@@]3([h])cc[c@]12c)[c@h](c)\c=c\[c@h](c)c(c)c) (aka 5alpha-ergosta-7,22-diene-3beta,5-diol)
J: None of the above. | J |
<Instruct>: Given the context 'Histological analysis
Eyes from at least 2 mice of the listed strains were fixed (4% paraformaldehyde or Fekete's acid-alcohol-formalin fixative) processed, paraffin embedded and sectioned as previously reported [15,79], except that the paraformaldehyde was buffered with 0.1 M phosphate buffer.', select the correct biomedical concept corresponding to 'formalin'. Answer using one of the provided options. | <Options>: A: ccc(c(o)=o)c1ccccc1 (aka 2-phenylbutyric acid)
B: lactaldehyde (2-hydroxypropionaldehyde) (aka lactaldehyde)
C: 3-[(4-[(3-oxopropyl)amino]butyl)amino]propionaldehyde
D: tributin (aka tributyrin)
E: [h]c(=o)ccn (aka 3-aminopropanal)
F: [h]c(=cc=o)c(o)ccccc (aka 4-hydroxynon-2-enal)
G: propanals
H: sarmentogenin (c[c@]12c[c@@h](o)[c@h]3[c@@h](cc[c@@h]4c[c@@h](o)cc[c@]34c)[c@@]1(o)cc[c@@h]2c1=cc(=o)oc1) (aka sarmentogenin)
I: 7-deaza-7-carbamoyladenosine (aka sangivamycin)
J: np(=o)(occc=o)n(cccl)cccl (aka aldophosphamide)
K: None of the above. | K |
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 14